<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92979</article-id><article-id pub-id-type="doi">10.7554/eLife.92979</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92979.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Surprising features of nuclear receptor interaction networks revealed by live-cell single-molecule imaging</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dahal</surname><given-names>Liza</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5600-1673</contrib-id><email>dahal.liza472@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Thomas GW</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5189-4313</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Dailey</surname><given-names>Gina M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8988-963X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Heckert</surname><given-names>Alec</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8748-6645</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Tjian</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Darzacq</surname><given-names>Xavier</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2537-8395</contrib-id><email>darzacq@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Department of Molecular and Cell Biology</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, University of California</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Eikon Therapeutics Inc, Hayward, California</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Stasevich</surname><given-names>Timothy J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03k1gpj17</institution-id><institution>Colorado State University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>01</month><year>2025</year></pub-date><volume>12</volume><elocation-id>RP92979</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-10-02"><day>02</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-02"><day>02</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.09.16.558083"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-17"><day>17</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92979.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-05"><day>05</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92979.2"/></event></pub-history><permissions><copyright-statement>© 2023, Dahal et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Dahal et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92979-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92979-figures-v1.pdf"/><abstract><p>Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>single-molecule tracking</kwd><kwd>nuclear receptors</kwd><kwd>transcription factors</kwd><kwd>gene regulatory networks</kwd><kwd>molecular biophysics</kwd><kwd>protein-protein interactions</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U54-CA231641-01659</award-id><principal-award-recipient><name><surname>Darzacq</surname><given-names>Xavier</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Tjian</surname><given-names>Robert</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001033</institution-id><institution>Jane Coffin Childs Memorial Fund for Medical Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Graham</surname><given-names>Thomas GW</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 GM098218</award-id><principal-award-recipient><name><surname>Heckert</surname><given-names>Alec</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Type II nuclear receptors do not always compete for a limiting pool of their obligate partner RXRa.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Complex intersecting regulatory networks govern critical transcriptional programs to drive various cellular processes in eukaryotes. These networks involve multiple transcription factors (TFs) binding shared cis-regulatory elements to elicit coordinated gene expression (<xref ref-type="bibr" rid="bib21">Gerstein et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Pan et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Reményi et al., 2004</xref>). A distinct layer of combinatorial logic occurs at the level of specific TF-TF interactions, which can direct TFs to distinct genomic sites. Thus, fine-tuning of TF-TF interactions can modulate TF-gene interactions to orchestrate differential gene expression. Often, dimerization between different members of a protein family can generate TF-TF combinations with distinct regulatory properties resulting in functional diversity and specificity (<xref ref-type="bibr" rid="bib44">Nandagopal et al., 2022</xref>; <xref ref-type="bibr" rid="bib49">Puig-Barbé et al., 2023</xref>). For example, E-box TFs of the basic helix-loop-helix (bHLH) family such as MYC/MAD share a dimerization partner MAX. Several studies have shown that switching of heterocomplexes between MYC/MAX and MAD/MAX results in differential regulation of genes and cell fate (<xref ref-type="bibr" rid="bib1">Amati et al., 1993</xref>; <xref ref-type="bibr" rid="bib5">Bouchard et al., 2001</xref>; <xref ref-type="bibr" rid="bib32">Hurlin and Huang, 2006</xref>; <xref ref-type="bibr" rid="bib65">Xu et al., 2001</xref>).</p><p>Type II nuclear receptors (T2NRs) present another classic example of such a dimerization network wherein the distribution of heterodimeric species regulates gene expression (<xref ref-type="bibr" rid="bib10">Bwayi et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Chan and Wells, 2009</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>). T2NRs constitute an extensive group of basic leucine zipper TFs that share a common modular structure composed of a well-conserved ligand binding domain (LBD) that mediates heterodimerization with their obligate partner retinoid X receptor (RXR) and a highly conserved DNA binding domain that recognizes consensus sequences termed direct response elements (<xref ref-type="bibr" rid="bib18">Evans and Mangelsdorf, 2014</xref>). Unlike Type I nuclear receptors, T2NRs do not depend on ligand binding for DNA engagement. Rather, binding of ligands to the LBD of chromatin- associated T2NR heterodimers results in eviction of co-repressors and recruitment of co-activators (<xref ref-type="bibr" rid="bib18">Evans and Mangelsdorf, 2014</xref>; <xref ref-type="bibr" rid="bib41">McKenna and O’Malley, 2002</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Endogenous Halo-tagging of RARa and RXRa to characterize their diffusive behavior.</title><p>(<bold>A</bold>) Schematic showing Type II nuclear receptors (T2NRs) like RXR-RAR bind direct response elements (DREs) as heterodimers to activate or repress transcription by recruiting co-activators (in presence of ligand) or co-repressors (in absence of ligand). A competitive interaction network between the obligate heterodimeric partner RXR with other T2NRs acts as a complex regulatory node for gene expression. Mechanistic features of protein-protein interaction within this regulatory node and its effect on chromatin binding in live cells are yet to be explored. (<bold>B</bold>) Cartoon showing Halo-tagging scheme of RARa and RXRa along with western blots of U2OS wild-type (WT) and knock-in (KI) RARa (left) and RXRa (right) homozygous clones. (<bold>C</bold>) Fast single-molecule tracking (fSMT). Likelihood of diffusion coefficients based on model of Brownian diffusion with normally distributed localization error for H2B-Halo (black), Halo-NLS (gray), RARa clones (blue), and RXRa clones (red) with black lines on top of the figure illustrating bound and moving populations. Each line represents a nucleus. (<bold>D</bold>) Diffusive spectra, probability density function (top), and cumulative distribution function (CDF) (bottom) - with drawing illustrating bound states as heterodimers of RARa and RXRa bound to chromatin.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Includes one PDF file explaining original western blots probing RAR clones with anti-RAR and anti-Flag along with relevant loading controls for <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, which are cropped and full-length versions respectively, of the same gels.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Includes one PDF file explaining original western blots probing RAR clones with anti-Halo along with relevant loading controls for <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, which are cropped and full-length versions respectively, of the same gels.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig1-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Includes one PDF file explaining original western blots probing RXR clones with anti-RXR (C-term) and anti-RXR (N-term) along with relevant loading controls for <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>, which are cropped and full-length versions respectively, of the same gels.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig1-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Includes one PDF file explaining original western blots probing RXR clones with anti-Halo and anti-V5 along with relevant loading controls for <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>, which are cropped and full-length versions respectively, of the same gels.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig1-data4-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Includes six raw images (tif) of western blots probing RAR clones with anti-RAR and anti-Flag along with relevant loading controls, displayed in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><caption><title>Includes four raw images (tif) of western blots probing RAR clones with anti-Halo along with relevant loading controls, displayed in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata7"><label>Figure 1—source data 7.</label><caption><title>Includes six raw images (tif) of western blots probing RXR clones with anti-RXR (C-term) and anti-RXR (N-term) along with relevant loading controls, displayed in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata8"><label>Figure 1—source data 8.</label><caption><title>Includes six raw images (tif) of western blots probing RXR clones with anti-Halo and anti-V5 along with relevant loading controls, displayed in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Verification of endogenous tagging and single-molecule tracking (SMT) analysis.</title><p>(<bold>A</bold>) Genotyping gels showing selected homozygously Halo-tagged (HT) RARα (c156, c239, and c258) and RXRα (C10, D6, and D9) clones. (<bold>B</bold>) Co-immunoprecipitation of overexpressed, HT RARα (left) and RXRα (right) in Cos7 cells. V5-tagged RXRα was immunoprecipitated and HT RARα was immunoblotted (left). HT RXRα was immunoprecipitated and Flag-tagged RARα was immunoblotted (right). (<bold>C</bold>) Luciferase assays showing retinoic acid responsive promoter activity of wild-type (WT) and HT RARα (top) and RXRα (bottom) clones in presence and absence of all-trans retinoic acid (atRA). (<bold>D</bold>) Confocal images of HT RARα (top) and RXRα (bottom) showing nuclear localization. (<bold>E</bold>) Subsampling knock-in (KI) RARα-Halo (blue, top) and Halo-RXRα (red, bottom) trajectories from fast SMT (fSMT) used to estimate <italic>f</italic><sub>bound</sub>. Sampling (with replacement) was done by number of trajectories (100, 1000, 5000, 10,000, and 12,500) extracted from varying number of cells (11, 22, 33, and 44). For each sample size, 100 replicates were performed and plotted as box plot showing variation and cross (x) indicating the mean.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw images shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Includes eight raw images (tif) for co-immunoprecipitation (co-IP) western blots displayed in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Full-length western blots of wild-type (WT) U2OS cells and homozygously Halo-tagged RARα and RXRα knock-in (KI) clones.</title><p>(<bold>A</bold>) RARα is detected in WT and KI clones using a specific antibody against RARα. RARα is also detected in KI clones using a specific antibody against Halo and Flag-tag. The lower part of the membrane was cut and blotted for Centrin2 as a loading control. (<bold>B</bold>) RXRα is detected in WT and KI clones using a specific antibody against a C-terminal epitope of RXRα. Since this antibody also recognizes other isoforms of RXR (~54 kDa), we validated RXRα expression by using an N-term epitope-specific antibody of RXRα. But this epitope sequence is disrupted by Halo-tagging at the N-terminal due to which it does not recognize HT-RXRα in KI clones. Our genotyping gels (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) give a clean single band confirming homozygous tagging and Sanger sequencing confirmed correct tagging. RXRα is also detected in KI clones using a specific antibody against Halo and V5-tag which show a clean gel confirming correct Halo-tagged RXRα product. The lower part of the membrane was cut and blotted for Centrin2 as a loading control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Diffusion behavior of endogenous RARα and RXRα with and without all-trans retinoic acid (atRA) treatment.</title><p>Diffusion spectra and cumulative distribution function of knock-in (KI) (<bold>Α</bold>) RARα-Halo and (<bold>B</bold>) Halo-RXRα in absence and presence of atRA. Cells were treated without or with 1 nm, and 100 nM atRA for 24 hr before single-molecule tracking (SMT) experiments. Dimethyl sulfoxide (DMSO) was added to cells without atRA treatment as a control. (<bold>C</bold>) Cellular abundance of KI RARα and RXRα with or without 24 hr treatment with atRA using flow cytometry analysis. Y-axis of bar plot shows number of Halo-tagged RARα and RXRα molecules. Error bars represent stdev of mean for three biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Diffusion coefficient and frame cut-off analysis in single-molecule tracking (SMT) data.</title><p>(<bold>A</bold>) Bar plot showing <italic>f</italic><sub>bound</sub>% of knock-in (KI) Halo-tagged (HT) RARα (c156) and RXRα (D6) calculated with cut-off of 0.1 (μm<sup>2</sup>/s) and 0.15 (μm<sup>2</sup>/s) diffusion coefficients. (<bold>B</bold>) Bar plot showing <italic>f</italic><sub>bound</sub>% of KI HT RARα (c156) and RARα overexpressed (OE) calculated with cut-off of 0, 500, 1000, and 1500 frames. Error bars denote stdev of bootstrapping mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig1-figsupp4-v1.tif"/></fig></fig-group><p>As the common obligate partner of many other TFs, MAX and RXR are thought to act as the ‘core’ for their respective dimerization networks. It has been postulated that availability of such core TFs is likely to be limited in cells, resulting in competition between the various partner TFs involved in the network (<xref ref-type="bibr" rid="bib12">Chan and Wells, 2009</xref>; <xref ref-type="bibr" rid="bib60">Walker et al., 2005</xref>). Indeed, early studies using purified proteins revealed that MAD and MYC compete for binding to MAX with equal affinities, and reduced complex formation was seen for either heterodimer with increasing amounts of a competing partner (<xref ref-type="bibr" rid="bib2">Ayer et al., 1993</xref>; <xref ref-type="bibr" rid="bib3">Baudino and Cleveland, 2001</xref>). Similarly, the T2NRs liver X receptor (LXR) and peroxisome proliferator-activated receptor (PPAR) were observed in vitro to have reduced binding to their respective response elements in the presence of competing T2NRs (<xref ref-type="bibr" rid="bib33">Ide et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Matsusue et al., 2006</xref>; <xref ref-type="bibr" rid="bib66">Yoshikawa et al., 2003</xref>).</p><p>Whether such in vitro systems would capture the complexity and competitive dynamics at play in live cells has remained an unresolved issue. Moreover, to date, in vivo studies of competitive heterodimerization networks have not examined TFs at endogenous expression levels and thus may not accurately recapitulate their dynamic interactions with each other and with chromatin (<xref ref-type="bibr" rid="bib19">Fadel et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Grinberg et al., 2004</xref>) or do not account for expression levels of relevant TFs in individual cells due to the population averaging nature of most such studies (<xref ref-type="bibr" rid="bib53">Rehó et al., 2023</xref>). To overcome these potential shortcomings, we employed fast single-molecule tracking (fSMT) (<xref ref-type="bibr" rid="bib4">Boka et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dahal et al., 2023</xref>; <xref ref-type="bibr" rid="bib17">Elf et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Hansen et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Hansen et al., 2017</xref>) and its newly developed complement, proximity-assisted photoactivation (PAPA-SMT) (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>) to test the effects of varying the stoichiometry of a core TF (RXRα) and its partner TF (RARα). We find that, contrary to expectations, the core component in cancer cells is not limiting but rather is in sufficient excess to accommodate more RARα even in the presence of many other endogenous partner T2NRs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Live-cell SMT of KI Halo-tagged RAR and RXR</title><p>As an initial test case for studying T2NR interactions, we focused on the heterodimeric partners RARα and RXRα, which are endogenously expressed alongside various other T2NRs in U2OS cells, a well-established cancer cell line for SMT (<xref ref-type="bibr" rid="bib25">Hansen et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">McSwiggen et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>). Using CRISPR/Cas9-mediated genome editing, we generated clonal lines with homozygous knock-in (KI) of HaloTag at the N-terminus of RXRα and the C-terminus of RARα (<xref ref-type="bibr" rid="bib28">Heckert et al., 2022b</xref>; <xref ref-type="bibr" rid="bib38">Los et al., 2008</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Western blotting confirmed that RARα and RXRα were tagged appropriately and expressed at similar levels to the untagged proteins (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), while co-immunoprecipitation (co-IP) experiments verified that Halo-tagged RARα and RXRα heterodimerize normally as expected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). In addition, we confirmed using luciferase assays that the RAR ligand, all-trans retinoic acid (atRA), activated retinoic acid responsive element (RARE)-driven gene expression in wild-type and homozygously edited clones, confirming the normal transactivation function of the tagged proteins (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Confocal live-cell imaging of cells stained with Janelia Fluor X 549 (JFX549) Halo ligand displayed normal nuclear localization of both Halo-tagged RARα and RXRα (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p><p>To evaluate how RARα and RXRα explore the nuclear environment and interact with chromatin, we used fSMT with a recently developed Bayesian analysis method, SASPT (<xref ref-type="bibr" rid="bib28">Heckert et al., 2022b</xref>), to infer the underlying distribution of diffusion coefficients within the molecular population, yielding a ‘diffusion spectrum’ (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). From these diffusion spectra we can extract quantitative parameters of subpopulations (peaks) such as mean diffusion coefficients and fractional occupancy, allowing us to measure the chromatin-bound fraction (<italic>f</italic><sub>bound</sub>) in live cells (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). To benchmark our SMT measurements, we first compared the diffusion spectra of RARα-Halo and Halo-RXRα to that of H2B-Halo (which as expected is largely chromatin-bound) and Halo-3×NLS (which is mostly unbound). We observed that RARα and RXRα both exhibit a clearly separated slow diffusing population (&lt;0.15 μm<sup>2</sup>/s) along with a faster mobile population (1–10 μm<sup>2</sup>/s) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The former we classify as ‘bound’ since it represents molecules diffusing at a rate indistinguishable from that of Halo-H2B (chromatin motion). The proportion of molecules diffusing at &lt;0.15 μm<sup>2</sup>/s is henceforth designated as <italic>f</italic><sub>bound</sub>. In comparison with Halo H2B (<italic>f</italic><sub>bound</sub> = 75.5 ± 0.7%) and Halo-NLS (<italic>f</italic><sub>bound</sub> = 10 ± 0.9%), RARα and RXRα have intermediate levels of chromatin binding (<italic>f</italic><sub>bound</sub> of 50 ± 3.0% and 38 ± 3.5%, respectively) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The <italic>f</italic><sub>bound</sub> was reproducible between three clonal cell lines of RARα (49 ± 1%, 47 ± 1%, 53 ± 1%) and RXRα (36 ± 1%, 36 ± 1%, 42 ± 1%). Finally, although recent studies have reported an increase in chromatin interaction upon agonist treatment (<xref ref-type="bibr" rid="bib9">Brazda et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Brazda et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Rehó et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Rehó et al., 2020</xref>), we did not observe a significant change in <italic>f</italic><sub>bound</sub> of RARα and RXRα upon atRA treatment, nor did atRA treatment appear to alter the fast-moving populations of RARα and RXRα (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A and B</xref>). These results are consistent with the classic model in which dimerization and chromatin binding of T2NRs are ligand independent.</p></sec><sec id="s2-2"><title>Chromatin binding of RARα and RXRα can be saturated in live cells</title><p>Chromatin binding by an individual TF within a dimerization network is predicted to be sensitive to its expression level (<xref ref-type="bibr" rid="bib35">Klumpe et al., 2023</xref>). To test how the expression levels of RARα and RXRα affect <italic>f</italic><sub>bound</sub>, we overexpressed Halo fusions from stably integrated transgenes in U2OS cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). After confirming transgene expression by western blotting (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), we compared the abundance of endogenous and exogenous Halo-tagged RARα and RXRα using flow cytometry (<xref ref-type="bibr" rid="bib11">Cattoglio et al., 2019</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Average cellular abundance of endogenous RARα and RXRα obtained from biological replicates of each homozygous clone were similar (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In contrast, expression of exogenous RARα-Halo was approximately four times that of the endogenous protein, while expression of Halo-RXRα was nearly twenty times that of endogenous RXRα (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Chromatin binding of overexpressed RARα was reduced by approximately half compared to endogenous (<italic>f</italic><sub>bound</sub> = 27 ± 0.72%) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), while that of overexpressed RXRα was decreased even more dramatically to 11 ± 0.75% - a value barely above the <italic>f</italic><sub>bound</sub> of the Halo-NLS control (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Using nuclear fluorescence intensity as a rough proxy for protein concentration in individual cells, we observed a negative correlation in single cells between TF concentration and <italic>f</italic><sub>bound</sub> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). These results imply that chromatin binding of both RARα and RXRα in U2OS cells is saturable - i.e., the total number of chromatin-bound molecules does not increase indefinitely with expression level but is in some way limited.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Chromatin binding of RARα and RXRα can be saturated and is limited by RARα.</title><p>(<bold>A</bold>) Schematic and western blot of stably integrated EF1α promoter-driven Halo-tagged (HT) RARα (left) and RXRα (right) overexpression in wild-type (WT) U2OS cells. (<bold>B</bold>) Bar plot; y-axis shows number of HT knock-in (KI) and overexpressed (OE) RARα (blue) and RXRα (red) molecules quantified using flow cytometry. (<bold>C</bold>) Bar plot; y-axis depicts chromatin-bound fraction (<italic>f</italic><sub>bound</sub>%) of KI and OE RARα, RXRα compared to Halo-NLS (control). (<bold>D</bold>) Assay condition schematics to determine which of the partners in the RARα/RXRα heterodimer complex is limiting for chromatin binding; parental KI HT RARα or RXRα clones with OE SNAP (orange), SNAP-RXRα (brown), RARα-SNAP (light blue), and RARα<sup>RR</sup>-SNAP (pink) using stably integrated EF1α promoter-driven transgene. (<bold>E</bold>) Bar chart; y-axis denotes number of KI HT RARα and RXRα molecules (depicted as blue and red cartoon respectively with ‘H’ labeled star attached) in presence or absence of transgene products. Error bars denote stdev of the mean from three biological replicates. (<bold>F</bold>) Bar plot showing <italic>f</italic><sub>bound</sub>% of KI HT RARα and RXRα in presence or absence of exogenously expressed SNAP proteins. Error bars for (<bold>B</bold>), (<bold>E</bold>) denote stdev of the mean from three biological replicates. Error bars for (<bold>C</bold>), (<bold>F</bold>) represent stdev of bootstrapping mean. p-Value≤0.001 (***), ≤0.01 (**), and ≤0.05 (*).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw images in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, along with the loading controls.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Includes eight raw images (tif) for western blots displayed in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, along with the loading controls.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cellular abundance and diffusion behavior of overexpressed Halo-tagged (HT) RARα and RXRα.</title><p>(<bold>A</bold>) Cellular abundance of HT knock-in (KI) versus overexpressed (OE) RARα and RXRα compared with standard Halo-CTCF cell line using flow cytometry analysis. X-axis shows TMR fluorescence intensity of HT molecules in U2OS cells. (<bold>B</bold>) Likelihood of diffusion coefficients for OE HT RARα and RXRα. Each line represents a nucleus. Diffusion spectra showing probability density function and cumulative distribution function for OE HT RARα and RXRα is shown underneath. (<bold>C</bold>) <italic>f</italic><sub>bound</sub>% of KI and overexpressed HT RARα and RXRα extracted from single cells plotted against mean nuclear intensity of single cells. Each dot represents a data collected from a single nucleus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Verification of mutant RARα (RARα<sup>RR</sup>) and exogenous SNAP-tagged protein expression.</title><p>(<bold>A</bold>) Rosetta modeled structure of the ligand binding domain (LBD) of RARα (pale blue) and RXRα (pale red) heterodimer (PDB code: 1DKF) with point mutation M379R and T382R. Original residues M379 and T382 are shown as cyan sticks and substituted residue arginine (R) is shown as pink sticks. Below the PDB structure is a schematic representation of M379R,T382R mutation in RARα (RARα<sup>RR</sup>) along with co-immunoprecipitation in Cos7 cells. V5-tagged RXRα was immunoprecipitated and RARα<sup>RR</sup> was immunoblotted. RARα<sup>RR</sup> disrupts heterodimerization with RXRα. (<bold>B</bold>) Cellular abundance of knock-in (KI) Halo-tagged (HT) RARα and RXRα in presence of overexpressed (OE) SNAP proteins using flow cytometry (FCM) analysis. FCM estimated fluorescence of TMR labeled HT RARα and RXRα molecules were compared with Halo-CTCF in U2OS along with unlabeled U2OS control. (<bold>C</bold>) Fluorescent gels and (<bold>D</bold>) western blots showing HT KI RARα and RXRα along with OE SNAP proteins in stably integrated conditions. U2OS cells were labeled with Halo ligand JFX549 (100 nM) and SNAP ligand SF650 (50 nM) before lysis.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw images shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig2-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Includes four raw images (tif) for co-immunoprecipitation (co-IP) western blots displayed in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata3"><label>Figure 2—figure supplement 2—source data 3.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw fluorescent gel images shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig2-figsupp2-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata4"><label>Figure 2—figure supplement 2—source data 4.</label><caption><title>Includes four raw images (tif) for fluorescent gels displayed in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-figsupp2-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata5"><label>Figure 2—figure supplement 2—source data 5.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw western blot images for RAR-Halo w/ SNAP transcripts, as shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig2-figsupp2-data5-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata6"><label>Figure 2—figure supplement 2—source data 6.</label><caption><title>Includes one file (pdf) containing and explaining each of the raw western blot images for Halo-RXR w/ SNAP transcripts, as shown in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-92979-fig2-figsupp2-data6-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata7"><label>Figure 2—figure supplement 2—source data 7.</label><caption><title>Includes six raw images (tif) of western blot images for RAR-Halo w/ SNAP transcripts displayed in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-figsupp2-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata8"><label>Figure 2—figure supplement 2—source data 8.</label><caption><title>Includes six raw images (tif) of western blot images for Halo-RXR w/ SNAP transcripts displayed in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92979-fig2-figsupp2-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Live-cell confocal images to verify protein expression.</title><p>(<bold>A</bold>) Confocal images of overexpressed (OE) Halo-tagged (HT) RARα and RXRα. Confocal images of U2OS cells expressing knock-in (KI) HT (<bold>B</bold>) RARα and (<bold>C</bold>) RXRα in presence of stably integrated OE SNAP proteins. HT molecules were labeled with 100 nM JFX549, and SNAP-tagged (ST) molecules were labeled with SF-650.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Fast single-molecule tracking (fSMT) of Halo-tagged (HT) RARα and RXRα with (w/) different transgene products.</title><p>(<bold>A</bold>) Likelihood diffusion coefficients and (<bold>B</bold>) diffusion spectra, probability density function (top), and cumulative distribution function (bottom) for knock-in (KI) HT RARα (left) and RXRα (right) in absence and presence of stably integrated overexpressed (OE) SNAP proteins. Each line in (<bold>A</bold>) represents a nucleus. <italic>f</italic><sub>bound</sub>% reported shows chromatin binding of RXRα is limited by the availability of RARα but not vice versa. Cartoon above the spectra illustrates bound population as heterodimers of RARα and RXRα bound to chromatin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Single-molecule tracking (SMT) analysis to verify change in <italic>f</italic><sub>bound</sub>% with respect to mean intensity.</title><p>(<bold>A</bold>) <italic>f</italic><sub>bound</sub>% of knock-in (KI) Halo-tagged (HT) RXRα in presence of overexpressed RARα-SNAP and RARα<sup>RR</sup>-SNAP extracted from single cells plotted against mean nuclear intensity of single cells. Each dot represents a data collected from a single nucleus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig2-figsupp5-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>RARα limits chromatin binding of RXRα</title><p>We next assessed how overexpression of RARα and RXRα affects <italic>f</italic><sub>bound</sub> of the endogenous proteins by stable integration of SNAP-tagged RARα or RXRα transgenes in Halo-KI RARα and RXRα cell lines (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). As controls, we also stably integrated transgenes expressing SNAP-NLS or a SNAP-tagged dimerization-incompetent RARα (RARα<sup>RR</sup>) (<xref ref-type="bibr" rid="bib6">Bourguet et al., 2000</xref>; <xref ref-type="bibr" rid="bib67">Zhu et al., 1999</xref>; <xref ref-type="fig" rid="fig2">Figure 2D</xref>). We validated disruption of the RARα<sup>RR</sup>-RXRα interaction using Rosetta modeling (<xref ref-type="bibr" rid="bib55">Shringari et al., 2020</xref>) and co-IP (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Using flow cytometry, fluorescent gels, and western blots, we first assessed if transgene expression alters expression of endogenous Halo-tagged RARα and RXRα (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–D</xref>). While no drastic changes in the cellular abundance of KI Halo-tagged RARα or RXRα was observed in the presence of SNAP, SNAP-RXRα, or RARα<sup>RR</sup>-SNAP proteins, the abundance of KI Halo-tagged RARα was approximately halved when RARα-SNAP was overexpressed (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). This is likely distinct from previously reported ligand-dependent RARα degradation (<xref ref-type="bibr" rid="bib58">Tsai et al., 2023</xref>; <xref ref-type="bibr" rid="bib67">Zhu et al., 1999</xref>) (see Discussion).</p><p>We then carried out a series of fSMT experiments to understand how <italic>f</italic><sub>bound</sub> of the endogenous RARα or RXRα is altered when its binding partner is present in excess (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref>). Surprisingly, we found that the <italic>f</italic><sub>bound</sub> of endogenous RARα-Halo (47 ± 1%) was largely unchanged upon expression of RXRα-SNAP (49 ± 1%), consistent with the control SNAP (47 ± 1%) (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>), implying that RARα <italic>f</italic><sub>bound</sub> is not limited by the availability of RXR. In contrast, RARα-SNAP expression significantly decreased chromatin binding of endogenous RARα-Halo to 29 ± 5% (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>). However, overexpression of mutant RARα<sup>RR</sup>-SNAP did not change the <italic>f</italic><sub>bound</sub> of endogenous RARα (43 ± 4%) (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>), suggesting that heterodimerization with RXRα is required for this effect.</p><p>In the reciprocal experiment with endogenous Halo-RXRα, the initial <italic>f</italic><sub>bound</sub> (35 ± 1%) was barely altered by overexpression of SNAP (38 ± 1%) or RARα<sup>RR</sup>-SNAP (35 ± 1%). As expected, overexpression of SNAP-RXRα reduced the <italic>f</italic><sub>bound</sub> of endogenous Halo-RXRα to 16 ± 2%. In contrast to RARα, however, overexpression of RARα-SNAP increased the <italic>f</italic><sub>bound</sub> of endogenous Halo-RXRα to 56 ± 1%. This result suggests that endogenous RXRα chromatin binding is limited by the availability of RAR (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>), and not due to limiting amounts of the universal dimer core partner RXR as would be expected based on current models in the literature.</p><p>While it may seem paradoxical that RAR is limiting for RXR binding, given the similar number of molecules of endogenous RARα and RXRα per cell (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), this is likely due to the presence of other endogenous RXR paralogs (see <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref> and Discussion). It is also probable that some fraction of RXR binding to chromatin arises from other T2NRs that can produce chromatin binding-competent dimers with RXR (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>, and Discussion). Notwithstanding these complexities, the results of the above SMT measurements in the presence of varying amounts of partner TFs allow us to infer that endogenous RXRα is likely in excess while RXR partners are limiting in U2OS cells.</p></sec><sec id="s2-4"><title>PAPA-SMT shows that RARα-RXRα dimerization correlates with chromatin binding</title><p>The above results support a model in which the total RXR pool (including all paralogs) is in stoichiometric excess of its partners in U2OS cells. To more directly monitor RXR-RAR interactions, we employed a recently developed SMT assay by our lab, PAPA (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>). PAPA detects protein-protein interactions by using excitation of a ‘sender’ fluorophore with green light to reactivate a nearby ‘receiver’ fluorophore from a dark state (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref>). As an internal control, violet light is used to induce direct reactivation (DR) of receiver fluorophores independent of their proximity to the sender (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). See Appendix 1 for a more detailed description of the steps involved in a PAPA-SMT experiment.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Proximity-assisted photoactivation (PAPA)-single-molecule tracking (SMT) shows direct interaction between Halo-tagged (HT) knock-in (KI) and SNAP-tagged overexpressed RARα and RXRα in live cells.</title><p>(<bold>A</bold>) Schematic illustrates how PAPA signal is achieved. First, SNAP-tagged (ST) protein is labeled with ‘receiver’ fluorophore like JFX650 (star with letter ‘S’) and HT protein is labeled with ‘sender’ fluorophore like JFX549 (star with letter ‘H’). When activated by intense red light the receiver fluorophore goes into a dark state (gray star with S). Upon illumination by green light, the receiver and sender molecules distal to one another do not get photoactivated (red X) but receiver SNAP molecules proximal to the sender gets photoactivated (green ✓). Pulses of violet light can induce direct reactivation (DR) of receiver independent of interaction with the sender. PAPA experiments. (<bold>B</bold>) Plots showing PAPA versus DR reactivation. (<bold>C</bold>) Diffusion spectra of PAPA and DR trajectories obtained for ST proteins for the represented conditions; parental HT RARα KI cell, stably expressing RXRα-SNAP (brown, left panel), as well as parental HT RXRα KI cell stably expressing RARα-SNAP (light blue, middle panel) and RARα<sup>RR</sup>-SNAP (light pink, right panel). A linear increase in PAPA versus DR reactivation is seen for non-interacting SNAP controls and a sublinear increase is seen for interacting SNAP proteins. Respective colored lines show linear fits of the data (see residuals in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). SNAP control data are re-plotted in middle and right panels. Cartoon inside diffusion spectra depicts if the expressed HT and ST proteins are expected to interact or not. <italic>f</italic><sub>bound</sub>% errors represent stdev of bootstrapping mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Controls for proximity-assisted photoactivation (PAPA) experiments.</title><p>(<bold>A</bold>) Diffusion spectra of PAPA and direct reactivation (DR) trajectories obtained for SNAP proteins below each corresponding conditions presented as cartoons; the parental Halo-tagged (HT) RARα (left) and RXRα (right) knock-in (KI) cells stably expressing control SNAP protein (orange). Cartoon inside diffusion spectra depicts that the expressed Halo and SNAP proteins are not expected to interact. (<bold>B</bold>) Residuals of the linear fit for PAPA versus DR localizations for SNAP (orange) and SNAP-RXRα (brown) proteins in presence of HT RARα (left panel), as well as SNAP (orange), RARα<sup>RR</sup>-SNAP (light pink), and RARα-SNAP (light blue) proteins in presence of HT RXRα (right panel). Same SNAP control data are re-plotted in all plots shown in (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig3-figsupp1-v1.tif"/></fig></fig-group><p>We applied PAPA-SMT to cell lines expressing SNAP-tagged RARα and RXRα transgenes in the background of Halo-tagged endogenous RXRα or RARα, respectively (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). As controls, we also imaged SNAP-3×NLS and RARα<sup>RR</sup>-SNAP, which are not expected to interact with Halo-RARα or RXRα. First, we plotted the number of single-molecule localizations reactivated by green and violet light in each cell (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). As expected, a low level of background reactivation by green light was observed for SNAP negative control, reflecting the baseline probability that an unbound SNAP molecule will at some low level be close enough to Halo to observe PAPA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, orange points) (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>). Violet light-induced DR and green light-induced PAPA were linearly correlated as expected, since both are proportional to the number of receiver molecules. However, a greater PAPA signal was seen for the Halo-RXRα → RARα-SNAP and RARα-Halo → SNAP-RXRα combinations than for the negative control, consistent with direct protein-protein interactions (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The relation between DR and PAPA was sublinear (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, left and middle panel, see residuals of the linear fit in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), consistent with saturation of binding to the Halo-tagged component. In contrast, the ratio of PAPA to DR for Halo-RXRα → RARα<sup>RR</sup>-SNAP was similar to the SNAP negative control, confirming that PAPA signal depends on a functional RAR-RXR interaction interface (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, right panel).</p><p>Next, we compared the diffusion spectra of molecules reactivated by DR and PAPA (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). For both Halo-RXRα → RARα-SNAP and RARα-Halo → SNAP-RXRα combinations, PAPA trajectories had a substantially higher chromatin-bound fraction than DR trajectories, indicating that a greater proportion of SNAP-tagged RARα/RXRα binds chromatin when it is in complex with its Halo-tagged partner. Only a slight shift in bound fraction was seen for RARα<sup>RR</sup>-SNAP (<italic>f</italic><sub>bound,DR</sub> = 7.5 ± 0.6%; <italic>f</italic><sub>bound,PAPA</sub> = 11.1 ± 0.8%), comparable to that seen for the SNAP negative control (<italic>f</italic><sub>bound,DR</sub> = 7.1 ± 0.5% and <italic>f</italic><sub>bound,PAPA</sub> = 11.2 ± 0.9% for Halo-RXRα; <italic>f</italic><sub>bound,DR</sub> = 7.3 ± 0.4% and <italic>f</italic><sub>bound,PAPA</sub> = 9.3±0.7 for RARα-Halo) (see Discussion), confirming that RARα<sup>RR</sup> fails to form chromatin binding-competent heterodimers with RXR.</p><p>The enrichment of chromatin-bound molecules in the PAPA-reactivated population of both RAR and RXR is consistent with heterodimerization mediating chromatin binding, that is further validated by the low <italic>f</italic><sub>bound</sub> of the dimerization-incompetent mutant.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>According to the current consensus models for how nuclear receptor interaction networks operate, specific T2NRs members compete for a limited pool of the ‘core’ partner RXR in cells, thus establishing a competitive regulatory network (<xref ref-type="bibr" rid="bib12">Chan and Wells, 2009</xref>; <xref ref-type="bibr" rid="bib19">Fadel et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Rehó et al., 2023</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2005</xref>; <xref ref-type="bibr" rid="bib64">Wood, 2008</xref>; <xref ref-type="bibr" rid="bib66">Yoshikawa et al., 2003</xref>). However, previous in vivo studies were carried out with overexpressed proteins, limiting their ability to accurately address this model of competition (<xref ref-type="bibr" rid="bib19">Fadel et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Rehó et al., 2023</xref>). Here, we used SMT in live cells with endogenously tagged proteins and carefully controlled protein levels of two players, RARα and RXRα, in the T2NRs dimerization network, thereby directly addressing a fundamental question - whether RAR (partner) or RXR (core) is limiting for chromatin association.</p><p>In stark contrast to the generally accepted T2NR competition model, our results reveal that in U2OS cells, formation and chromatin binding of RAR-RXR heterodimers are limited by the concentration of RAR and not the core subunit RXR (<xref ref-type="fig" rid="fig4">Figure 4</xref>). PAPA-SMT directly confirmed in vivo that the association with RXRα promotes chromatin binding of RARα and vice versa (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). However, unexpectedly, overexpression of RARα increases <italic>f</italic><sub>bound</sub> of endogenous RXRα, while the reverse is not true (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), indicating that RXR is not limiting but is rather constrained by the availability of its binding partners. Note that even though the number of RXRα and RARα molecules is about the same and the heterodimer complex has a predicted 1:1 stoichiometry (<xref ref-type="bibr" rid="bib51">Rastinejad, 2022</xref>; <xref ref-type="bibr" rid="bib50">Rastinejad et al., 2000</xref>), the <italic>f</italic><sub>bound</sub> of endogenous RARα (50%) and RXRα (38%) differed by about 10% (<xref ref-type="fig" rid="fig1">Figures 1D</xref> and <xref ref-type="fig" rid="fig2">2B</xref>). This surprising result could be explained by expression of additional RXR isoforms (most likely RXRβ) in U2OS cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). The fact that the <italic>f</italic><sub>bound</sub> of overexpressed RARα decreases only twofold, even though it is in fourfold excess over endogenous RXRα, likewise suggests that there are other heterodimerization partners of RARα available (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, see <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>). Moreover, the <italic>f</italic><sub>bound</sub> of overexpressed RXR is essentially the same as the NLS control, indicating this excess core partner remains nearly totally unbound (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). This is consistent with endogenous RXR already being in excess such that any additional RXR would remain mostly monomeric and unbound to chromatin. Hence, despite not directly measuring the protein levels of all RXR isoforms, we can still deduce in U2OS cells that RXR is in excess relative to its binding partners.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A model for RARa limited chromatin binding of RARa-RXRa heterodimers.</title><p>(<bold>A</bold>) Pool of RXRα (red) and RXR partners (RARα - blue, other Type II nuclear receptors [T2NRs] - yellow) along with some number of chromatin-bound RARα-RXRα heterodimers exist under normal conditions. (<bold>B</bold>) When the pool of free RXRα is increased, the number of chromatin-bound RARα-RXRα heterodimers does not change. (<bold>C</bold>) When the pool of RARα is increased, chromatin binding of RARα-RXRα heterodimers increases, until it reaches saturation. Note: For simplicity we have omitted to show heterodimerization of other T2NRs (yellow) with RXRα (red).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92979-fig4-v1.tif"/></fig><p>Control of RAR-RXR heterodimer concentration by RAR abundance makes sense considering the observation that RAR protein levels appear to be regulated by multiple feedback mechanisms: First, we find that overexpression of RARα significantly lowers the expression of endogenous RARα (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) implying either that RAR participates in negative autoregulation at the transcriptional level or, that an excess of RAR causes instability at the protein level. We favor the latter possibility because overexpression of RARα reduces not only the expression of endogenous RARα but also its <italic>f</italic><sub>bound</sub> (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), indicating a reduction in dimerization and chromatin binding. It is possible that endogenous RAR may be more readily degraded when not bound by RXR, analogous to what was recently shown for the c-MYC/MAX heterodimers (<xref ref-type="bibr" rid="bib39">Mark et al., 2023</xref>). Second, as has been previously reported, RARα expression decreases upon ligand treatment (<xref ref-type="bibr" rid="bib34">Ismail and Nawaz, 2005</xref>; <xref ref-type="bibr" rid="bib36">Kopf et al., 2000</xref>; <xref ref-type="bibr" rid="bib45">Osburn et al., 2001</xref>; <xref ref-type="bibr" rid="bib58">Tsai et al., 2023</xref>; <xref ref-type="bibr" rid="bib67">Zhu et al., 1999</xref>). Curiously, a 50% reduction in RARα upon addition of ligand did not affect the <italic>f</italic><sub>bound</sub> of either RARα or RXRα (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A and B</xref>), suggesting that most chromatin binding of endogenous RXRα in U2OS cells depends on heterodimerization partners other than RARα (see <xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>).</p><p>In contrast to the generally accepted model, we thus envision a network of T2NR heterodimers not always driven by competition for the core TF partner (RXR). Instead, an excess of RXR may ensure independent regulation of the different T2NRs without disrupting crosstalk between them (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>In this first study, we have not examined other T2NRs expressed in U2OS cells or whether there is a similar excess of RXR in other cell types. Therefore, we cannot rule out that competition for RXR between T2NRs occurs in some cases since different cell types express RXR and partner T2NRs in varying amounts. It seems likely that chromatin binding by any given T2NR will depend on the concentrations of all other T2NRs. It is thus important to determine how interactions within the dimerization network are perturbed upon up- or down-regulation of one or more T2NRs, especially since dysregulation of T2NR expression has been reported in several types of cancers as well as other diseases (<xref ref-type="bibr" rid="bib7">Brabender et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Collins-Racie et al., 2009</xref>; <xref ref-type="bibr" rid="bib20">Frigo et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Long and Campbell, 2015</xref>). Here, we have shown that SMT and PAPA-SMT provide one empirical way to determine which set of components in a dimerization network is stoichiometrically limiting in a given cell type, without having to measure the concentration of every T2NR or the affinity of every interaction. The basic framework we have established here could also be extended to probe the effect of ligands or small molecules on the T2NR interaction network or other dimerization networks seen in bHLH or leucine zipper family of TFs, providing useful information about critical regulatory network interactions often implicated in diseases.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Cell culture and stable cell line generation</title><p>U2OS cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/l glucose supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan UT, Cat. #AE28209315), 1 mM sodium pyruvate (Thermo Fisher 11360070), L-glutamine (Sigma #G3126-100G), GlutaMAX (Thermo Fisher #35050061), and 100 U/ml penicillin-streptomycin (Thermo Fisher #15140122) at 37°C and 5% CO<sub>2</sub>. Cells were subcultured at a ratio of 1:4 to 1:10 every 2–4 days for no longer than 30 passages. Regular mycoplasma testing was performed using polymerase chain reaction (PCR). Phenol containing media was used for regular cell culture and phenol red-free DMEM (Thermo Fisher #21063029) supplemented with 10% FBS and 100 U/ml penicillin-streptomycin was used for imaging.</p><p>Stable cell lines expressing the exogenous gene products (<xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>) were generated by PiggyBac transposition and antibiotic selection. Gibson assembly was used to clone genes of interest into a PiggyBac vector containing a puromycin or neomycin resistant gene. Plasmids were purified by Zymo midiprep kit (Zymo D4200) and all cloning was confirmed by Sanger sequencing. Cells were transfected by nucleofection using the Lonza Cell line Nucleofector Kit V (Lonza, Basel, Switzerland, #VVCA1003) and the Amaxa Nucleofector II device. For each transfection cells were plated 1–2 days before nucleofection in a six-well plate until they reach 70–90% confluency. Cells were trypsinized, resuspended in DMEM media, and centrifuged at 200×<italic>g</italic> for 2 min before the media was aspirated. Cells were then resuspended in 100 µl Lonza transfection reagent (82 μl Kit V solution+16 μl of Supplement #VVCA1003) containing 0.4 μg of SuperPiggyBac transposon vector and 0.8 μg of donor PiggyBac plasmid and transferred to an electroporation cuvette. Cells were electroporated using program X-001 on the Amaxa Nucleofector II (Lonza). Transfected cells were cultured in DMEM growth media without any antibiotics for 24–48 hr and then selected for 10 days with 1 μg/ml puromycin (Thermo Fisher #A1113803) or 1 mg/ml neomycin (G418 Sulfate, Thermo Fisher #10131027). After selection polyclonal cell lines were maintained in the selection media containing required antibiotics.</p><p>For ligand treatment, 100 μM atRA stock was prepared by dissolving atRA powder (CAS No: 302794, Sigma-Aldrich #R2625) in dimethyl sulfoxide (DMSO) (Sigma-Aldrich #D2650) and was diluted 1:100,000 or 1:1000 in growth media to final concentration of 1 nM or 100 nM respectively. The same volume of DMSO used for 100 nM atRA treatment (0.1%) is used for the control group as a condition without atRA treatment. Cells were treated 24 hr in either atRA or DMSO alone before imaging.</p></sec><sec id="s4-2"><title>Genome editing cell lines</title><p>KI cell lines were generated as previously described (<xref ref-type="bibr" rid="bib25">Hansen et al., 2017</xref>) with some modifications. Halo-tagging of endogenous RARα was described in our previously published work (<xref ref-type="bibr" rid="bib28">Heckert et al., 2022b</xref>) which we have further validated for the current study. For Halo-tagging we designed sgRNAs using CRISPOR web tool (<xref ref-type="bibr" rid="bib15">Concordet and Haeussler, 2018</xref>). Since exon 1 of RXRα is very short (only 9 aa) we chose to gene edit at the start of exon 2 for a successful tagging. sgRNAs were cloned into the Cas9 plasmid (a gift from Frank Xie) under the U6 promoter (Zhang Lab) with an mVenus reporter gene under the PGK promoter. Repair vectors were cloned in a basic pUC57 backbone for N-terminal tagging and pBluescript II SK (+) (pBSKII+) backbone for C-terminal tagging, with 500 bp left and right homology arms on either side of the Halo-tag sequence. Two guide/repair for N-terminal and three guide/repair vector pairs for C-terminal were attempted; only-N-terminal clones were ultimately recovered. Each sgRNA/donor pair were transfected to approximately 1 million early passage U2OS cells, at 1:3 ratio of sgRNA/donor (total 5 μg DNA) and plated in a six-well plate. 48 hr after transfection, Venus-positive cells were FACS sorted and cultured for another 7–10 days. Then, Halo-positive cells (stained with TMR) were sorted individually into single wells of 96-well plates and cultured for another 12–14 days. Clones were expanded and genotyped using PCR. PCR was done using one primer upstream of the left homologous arm and the other primer downstream of the right homologous arm. Another PCR with either external primer paired with a corresponding internal primer located in the Halo-tag coding region was done for further validation. Homozygous clones with the correct genotype (V5-Halo-RXRα clones C10, D6, and D9) were confirmed by Sanger sequencing and western blotting.</p></sec><sec id="s4-3"><title>Antibodies</title><p>The following antibodies were used for western blotting: mouse monoclonal anti-RARα [H1920] (Abcam, #ab41934) diluted at 1:400, rabbit monoclonal anti-RXRα [EPR7106] (Abcam, #ab125001) diluted at 1:500, rabbit polyclonal anti-RXRα (Proteintech, #212181AP), mouse monoclonal anti-V5 tag (Thermo Fisher, #R960-25) diluted at 1:5000, mouse monoclonal anti-FLAG [M2] (Sigma-Aldrich, #F1804) diluted at 1:5000, mouse monoclonal anti-Halo (Promega, #G9211) diluted at 1:500, mouse monoclonal anti-TBP (Abcam, #ab51841) diluted at 1:5000, rabbit polyclonal anti-Centrin 2 (Proteintech, # 158771AP) diluted at 1:1000, goat polyclonal anti-mouse IgG light chain specific (Jackson ImmunoResearch, # 115035174) diluted at 1:10,000, mouse monoclonal anti-rabbit IgG light chain specific (Jackson ImmunoResearch, #211032171) diluted at 1:10,000.</p><p>The following antibodies were used for co-IP: rabbit polyclonal anti-V5 (Abcam, # ab9116) for immunoprecipitation, mouse monoclonal anti-FLAG [M2] (Sigma-Aldrich, #F1804) diluted at 1:5000 and mouse monoclonal anti-V5 tag (Thermo Fisher, #R960-25) diluted at 1:5000 for blotting.</p></sec><sec id="s4-4"><title>Western blotting</title><p>For western blots, cells growing in six-well or 10 cm plates at 80–90% confluency were scraped and pelleted in ice-cold phosphate-buffered saline (PBS) containing protease inhibitors. Cell pellets were resuspended using 500–1000 μl hypotonic buffer (100 mM NaCl, 25 mM HEPES, 1 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5% NP-40 alternative) containing protease inhibitors - 1× aprotinin (Sigma, #A6279, diluted 1:1000), 1 mM benzamidine (Sigma, #B6506), 0.25 mM PMSF (Sigma #11359061001), and 1× cOmplete EDTA-free Protease Inhibitor Cocktail (Sigma, #5056489001) along with 125 U/ml of benzonase (Novagen, EMD Millipore #71205-3). Resuspended cells were gently rocked at 4°C for at least 2 hr after which 5 M NaCl was added. Cells were left rocking for extra 30 min at 4°C and then centrifuged at max speed at 4°C. Supernatants were quantified using Bradford and 15–20 μg was loaded on 8% Bis-Tris SDS gel. Wet transfer to 0.45 μm nitrocellulose membrane (Thermo Fisher #45004031) was performed in a transfer buffer (15 mM Tris-HCl, 20 mM glycine, 20% methanol) for 60–80 min at 100 V, 4°C. Membranes were blocked in 10% non-fat milk in 0.1% TBS-Tween (TBS-T) for 1 hr at room temperature (RT) with agitation. Membranes were then blotted overnight with shaking at 4°C with primary antibodies diluted in TBS-T with 5% non-fat milk. After 5×5 min washes in 0.1% TBS-T, membranes were incubated at RT with HRP-conjugated light chain secondary antibodies diluted 1:10,000 in TBS-T with 5% non-fat milk, for 1 hr with agitation. After 5×5 min washes in 0.1% TBS-T, membranes were incubated for 2 min in freshly prepared Perkin Elmer LLC Western Lightning Plus-ECL, enhanced Chemiluminescence Substrate (Thermo Fisher, #509049326). Finally, membranes were imaged with Bio-Rad Chemidoc Imaging System (Bio-Rad, Model No: Universal Hood III).</p></sec><sec id="s4-5"><title>Luciferase assays</title><p>pGL3-RARE luciferase, a reporter containing firefly luciferase driven by SV40 promoter with three RAREs, a gift from T Michael Underhill (Addgene plasmid 13456; addgene:13458; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_13458">Addgene_13458</ext-link>; <xref ref-type="bibr" rid="bib31">Hoffman et al., 2006</xref>) was used for luciferase assays. A pRL-SV40 vector (Promega #E2261) expressing Renilla luciferase with SV40 promoter was used as a control to normalize luciferase activity. Cells were plated on six-well plate at least 48 hr before being co-transfected with 200 ng pGL3-RARE-luciferase and 10 ng Renilla luciferase vector, using TransIT-2020 Transfection Reagent (Mirus Bio, #MIR5404). A day after transfection, cells were treated with 100 nM atRA or 0.1% DMSO (control). Luciferase assay was performed the next day, using Dual-Luciferase Reporter Assay System (Promega, #E1910) according to the manufacturer’s protocol, on the Glomax Luminometer (Promega). The relative luciferase activity was calculated by normalizing firefly luciferase activity to the Renilla luciferase activity to control for transfection efficiency.</p></sec><sec id="s4-6"><title>Co-immunoprecipitation</title><p>For co-IP experiments, Cos7 cells were plated to 2×15 cm dishes for each condition, at 60–70% confluency. DNA Lipofectamine 3000 (Thermo Fisher #L3000015) was used to co-transfect the cells with plasmids expressing RARα-Halo-3×FLAG and RXRα-V5 or V5-Halo-RXRα and RARα-3×FLAG or RARα<sup>RR</sup>-Halo-3×FLAG and RXRα-V5. According to the manufacturer’s instructions, 500 μl Opti-MEM medium (Thermo Fisher #31985062) was combined with 20 μl P3000 reagent and the plasmids for each condition. To control for the ratio of transfected DNA to the reagents, total transfected DNA mass was kept at 10 μg for each condition using empty pBSK vector (Addgene # 212205). 500 μl Opti-MEM medium containing 20 μl Lipofectamine 3000 reagent was subsequently added to the plasmid containing mixture and incubated at RT for 15 min, after brief pipetting to mix the solutions. The mixture was then divided equally to the cells plated in 2×15 cm dishes. COS7 cells were cultured in DMEM media with 4.5 g/l glucose supplemented with 10% FBS, 1 mM sodium pyruvate, L-glutamine, GlutaMAX, and 100 U/ml penicillin-streptomycin and maintained at 37°C and 5% CO<sub>2</sub>.</p><p>Cells were collected from plates 48 hr after transfection by scraping in ice-cold 1× PBS with protease inhibitors (1× aprotinin, 0.25 mM PMSF, 1 mM benzamidine, and 1× cOmplete EDTA-free Protease Inhibitor Cocktail). Collected cells were pelleted, flash-frozen in liquid nitrogen, and stored at –80°C. On the day of co-IP experiments, cell pellets were thawed on ice, resuspended to 700 μl of cell lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 3 mM MgCl<sub>2</sub>, 340 mM sucrose [1.16gr], and 10% glycerol) with freshly added 10% Triton X-100. Cells were rocked at 4°C for 8 min to allow lysis and centrifuged for 3 min at 3000×<italic>g</italic>. The cytoplasmic fraction was removed, and the nuclear pellets were resuspended in 1 ml hypotonic buffer (100 mM NaCl, 25 mM HEPES, 1 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5% NP-40 alternative) containing protease inhibitors and 1 μl benzonase. After rocking for 2–3 hr at 4°C, the salt concentration was adjusted to 0.2 M NaCl final and the lysates were rocked for another 30 min at 4°C. Supernatant was removed after centrifugation at maximum speed at 4°C for 20 min and quantified by Bradford. Typically, 1 mg of protein was diluted in 1 ml 0.2 mM co-IP buffer (200 mM NaCl, 25 mM HEPES, 1 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5% NP-40 alternative) with protease inhibitors and cleared for 2 hr at 4°C with magnetic Protein G Dynabeads (Thermo Fisher, #10009D) before overnight immunoprecipitation with 1 μg per 250 μg of proteins of either normal serum IgGs or specific antibodies as listed above. Some precleared lysates were kept overnight at 4°C as input. Magnetic Protein G Dynabeads were also precleared overnight with 0.5% BSA at 4°C. Next day the precleared Protein G dynabeads were added to the antibody containing samples and incubated at 4°C for 2 hr. Samples were briefly spun down and placed in a magnetic rack at 4°C for 5 min to remove the co-IP supernatant. After extensive washes with the co-IP buffer, the proteins were eluted from the beads by boiling for 10 min in 1× SDS-loading buffer and analyzed by SDS-PAGE and western blot.</p></sec><sec id="s4-7"><title>Flow cytometry</title><p>Cells were grown in six-well dishes. On the day of the experiment, cells were labeled with 500 nM Halo-TMR for 30 min, followed by one quick wash with 1× PBS and 15 min wash in dye-free DMEM before trypsinization. Cells were pelleted after centrifugation, resuspended in fresh medium, filtered through 40 μm filtration unit, and placed on ice until fluorescence read out by Flow Cytometry (within 30 min). Using an LSR Fortessa (BD Biosciences) flow cytometer, live cells were gated using forward and side scattering and TMR fluorescence emission readout was filtered using 610/20 band pass filter after excitation with 561 nm laser. Mean fluorescence intensity of the samples and absolute abundance were calculated as described in <xref ref-type="bibr" rid="bib11">Cattoglio et al., 2019</xref>, using a previously quantified Halo-CTCF cell line as a standard (<xref ref-type="bibr" rid="bib11">Cattoglio et al., 2019</xref>).</p></sec><sec id="s4-8"><title>Cell preparation and dye labeling for imaging</title><p>For confocal imaging ~50,000 cells were plated in tissue culture-treated 96-well microplate (Perkin Elmer, #6055300) a day before imaging. Cells were labeled with Halo and/SNAP for 1 hr and incubated in dye-free media for 20 min after a quick 1× PBS wash to remove any free dye. Phenol-free media containing Hoechst (1 μM) was added to the cells and incubated for 1 hr before proceeding with imaging.</p><p>For SMT, 25 mm circular No. 1.5H precision coverglass (Marienfield, Germany, 0117650) were sonicated in ethanol for 10 min, plasma cleaned then stored in 100% isopropanol until use. ~250,000 U2OS cells were plated on sonicated, and plasma cleaned coverglass placed in six-well plates. For ligand treatment, cells were treated with DMSO (control, 0.1%), 1 nM atRA or 100 nM atRA, a day after plating cells in the coverslip and a day before imaging. After ~24–48 hr, cells were incubated with 100 nM PA-JFX549 dye in regular culture media for 30 min, followed by 4×30 min incubations with dye-free culture media at 37°C. A quick 2× PBS wash was interspersed between each 30 min dye-free media incubation. After the final wash, coverslips with plated cells facing upward were transferred to Attofluor Cell Chambers (Thermo Fisher, # A7816), and phenol-free media added for imaging. For Halo-tagged RARα and RXRα homozygous clones that were stably integrated with SNAP-tagged RARα, RXRα, or control transgenes under EF1α promoter; cells were double-labeled with 100 nM HaloTag ligand (HTL) PA-JFX549 and SNAP tag ligand (STL) 50 nM SF-650 simultaneously. The 30 min labeling step was followed by the same wash steps to remove free dye as described above, before transferring the coverslips to Attofluor Cell Chambers and imaging.</p><p>For PAPA-SMT experiments, polyclonal U2OS cells stably expressing SNAP-tagged RARα or RXRα under EF1α promoter within the endogenous Halo-tagged RARα and RXRα homozygous clones were used. ~400,000 polyclonal cells were plated in glass-bottom dishes (MatTEK P35G-1.5–20-C) and stained overnight with 50 nM JFX549 HTL and 5 nM JFX650 STL in phenol red-free DMEM (Thermo Fisher #21063029). Next day, cells were briefly rinsed twice with 1× PBS, incubated twice for 30 min in phenol red-free DMEM to remove free dye, and exchanged into fresh phenol red-free medium more before imaging.</p></sec><sec id="s4-9"><title>Confocal imaging</title><p>For confocal imaging, endogenously Halo-tagged cells were labeled with Halo ligand JFX549 (100 nM) and Hoechst (1.6 μM); endogenously Halo-tagged cells overexpressing SNAP-tagged proteins were labeled with Halo ligand JFX549 (100 nM), SNAP ligand SF650 (25 nM), and Hoechst (1.6 μM). Imaging was performed at the UC Berkeley High Throughput Screening facility on a Perkin Elmer Opera Phenix equipped with 37°C and 5% CO<sub>2</sub>, using a built-in ×40 water immersion objective.</p></sec><sec id="s4-10"><title>Live-cell SMT</title><p>All SMT experiments were performed using a custom-built microscope as previously described (<xref ref-type="bibr" rid="bib25">Hansen et al., 2017</xref>). Briefly, a Nikon TI microscope was equipped with a ×100/NA 1.49 oil immersion total internal reflection fluorescence (TIRF) objective (Nikon apochromat CFI Apo TIRF 100× Oil), a motorized mirror, a perfect Focus system, an EM-CCD camera (Andor iXon Ultra 897), laser launch with 405 nm (140 mW, OBIS, Coherent), 488 nm, 561 nm, and 639 nm (1W, Genesis Coherent) laser lines, an incubation chamber maintaining a humidified atmosphere with 5% CO<sub>2</sub> at 37°C. All microscope, camera, and hardware components were controlled through the NIS-Elements software (Nikon).</p><p>For tracking endogenous as well as overexpressed Halo-tagged proteins, PA-JFX549 labeled cells were excited with 561 nm laser at 2.3 kW/cm<sup>2</sup> with single band-pass emission filter (Semrock 593/40 nm for PA-JFX549). All imaging was performed using highly inclined optical sheet (HILO) illumination (<xref ref-type="bibr" rid="bib57">Tokunaga et al., 2008</xref>). Low laser power (2–3%) was used to locate and focus cell nuclei. Region of interest (ROI) of random size but with maximum possible area was selected to fit into the interior of the nuclei. Before tracking, 100 frames of continuous illumination with 549 laser (laser power 5%) at 80 ms per frame was recorded to later calculate mean intensity of each nuclei. After partial pre-bleaching (only for overexpressed Halo-tagged proteins), movies were taken with 1 ms pulses of full power of 561 nm illumination at the beginning of frame interval with camera exposure of 7 ms/frame, while the 405 nm laser (67 W/cm<sup>2</sup>) was pulsed during ~447 μs camera transition time. Total of 30,000 frames were collected. 405 nm intensity was manually tuned to maintain low density (1–5 molecules fluorescent particles per frame).</p><p>For tracking experiments with endogenous Halo-tagged proteins in the presence of transgenic SNAP protein products, cells were dual-labeled with both PA-JFX549 and STL-SF650. Before tracking cells were excited with a 639 nm laser at 88 W/cm<sup>2</sup> and single band-pass emission filter set to Semrock 676/37 nm. Low laser power (2–3%) was used to locate and focus cell nuclei. As before, ROI of random size but with maximum possible area was selected to fit into the interior of the nuclei. The emission filter was switched to Semrock 593/40 nm band-pass filter for PA-JFX549, keeping the TIRF angle, stage XYZ position, and ROI the same. Cells were then excited with 549 nm and single molecules were tracked for 30,000 frames as described above.</p><p>Note, we estimated that to calculate <italic>f</italic><sub>bound</sub> of RARα and RXRα with minimal bias and variation, we need to analyze at least 10,000 pooled trajectories from n≥20 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). Therefore, all analyses of fSMT to calculate <italic>f</italic><sub>bound</sub> or <italic>f</italic><sub>bound</sub> % presented in this paper are done accordingly. At least 8–10 movies were collected for each sample as one technical replicate on a given day. Two technical replicates on 2 separate days were collected to produce the reported results. As observed previously for SMT experiments (<xref ref-type="bibr" rid="bib43">McSwiggen et al., 2024</xref>), the variance within collected data was largely due to cell-to-cell variance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>).</p></sec><sec id="s4-11"><title>PAPA-SMT</title><p>PAPA-SMT imaging was performed using the same custom-built microscope described above using an automated system (<xref ref-type="bibr" rid="bib23">Graham et al., 2024</xref>; <xref ref-type="bibr" rid="bib61">Walther et al., 2024</xref>). Briefly, the microscope described above was programmed using Python and NIS Elements macro language code to raster in a grid over the coverslip surface, acquire an image in the JFX650 channel, identify cell nuclei, reposition the stage to center it on a target nucleus, resize the imaging ROI to fit the nucleus, pre-bleach JFX650 with red light (639 nm) for 5 s, and finally perform a PAPA-SMT illumination sequence. The illumination sequence consisted of 5 cycles of the following, at a frame rate of 7.48 ms/frame:</p><list list-type="order"><list-item><p>Bleaching: 200 frames of red light (639 nm), not recorded</p></list-item><list-item><p>Imaging: 30 frames of red light, one 2 ms stroboscopic pulse per frame, recorded</p></list-item><list-item><p>PAPA: 5 frames of green light (561 nm), not recorded</p></list-item><list-item><p>Imaging: 30 frames of red light, one 2 ms stroboscopic pulse per frame, recorded</p></list-item><list-item><p>Bleaching: 200 frames of red light, not recorded</p></list-item><list-item><p>Imaging: 30 frames of red light, one 2 ms stroboscopic pulse per frame, recorded</p></list-item><list-item><p>DR: 1 frames of violet light (405 nm), one 1 ms stroboscopic pulse, not recorded</p></list-item><list-item><p>Imaging: 30 frames of red light, one 2 ms stroboscopic pulse per frame, recorded</p></list-item></list><p>Laser power densities were approximately 67 W/cm<sup>2</sup> for 405 nm, 190 W/cm<sup>2</sup> for 561 nm, and 2.3 kW/cm<sup>2</sup> for 639 nm. This illumination sequence includes non-stroboscopic illumination periods to bleach fluorophores or place them back in the dark state (steps 1 and 5), and it records only the frames immediately before and after the PAPA and DR pulses. This is done to decrease file sizes and speed up subsequent analysis compared to our previous protocol (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>).</p></sec><sec id="s4-12"><title>SMT and SMT-PAPA data processing and analysis</title><p>All SMT movies were processed using the open-source software package <ext-link ext-link-type="uri" xlink:href="https://github.com/alecheckert/quot">quot</ext-link> (<xref ref-type="bibr" rid="bib29">Heckert and Fan, 2022</xref>). For SMT dataset quot package was run on each collected SMT movie using the following settings: [filter] start = 0; method = ‘identity’; chunk_size = 100; [detect] method = ‘llr’; k=1.0; w=15, t=18; [localize] method = ‘ls_int_gaussian’, window size = 9; sigma = 1.2; ridge = 0.0001; max_iter = 20; damp = 0.3; camera_gain = 109.0; camera_bg = 470.0; [track] method = ‘euclidean’; pixel_size_μm=0.160; frame interval = 0.00748; search radius = 1; max_blinks = 0; min_IO = 0; scale - 7.0. The first 500 or 1000 frames of each movie were removed due to high localization density. To confirm that all movies were sufficiently sparse to avoid misconnections, a maximum number of 5 localizations per frame was maintained (although most frames had 1 or less). To infer the distribution of diffusion coefficients from experimentally observed trajectories, we used the state array method, which is publicly available at <ext-link ext-link-type="uri" xlink:href="https://github.com/alecheckert/saspt">https://github.com/alecheckert/saspt</ext-link> (<xref ref-type="bibr" rid="bib27">Heckert et al., 2022a</xref>; <xref ref-type="bibr" rid="bib28">Heckert et al., 2022b</xref>). The following settings were used: likelihood_type = ‘rbme’; pixel_size_μm=0.16; frame_interval = 0.00747; focal depth = 0.7; start_frame = 500 or 1000 frames. RBME likelihood for individual cells and occupations as the mean of the posterior distribution over state occupations marginalized on diffusion coefficient is reported. For SMT movies in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>, mean intensity of each cell was calculated using the mean gray value tool in FIJI. Mean gray value of each frame (total 100 frames) of the pre-bleaching 80 ms movie was measured. Average mean gray value over the 100 frames is reported as mean intensity for each cell.</p><p>For PAPA-SMT quot package was run on each collected SMT movie using the following settings: [filter] start = 0; method = ‘identity’; chunk_size = 100; [detect] method = ‘llr’; k=1.2; w=15, t=18; [localize] method = ‘ls_int_gaussian’, window size = 9; sigma = 1.2; ridge = 0.0001; max_iter = 10; damp = 0.3; camera_gain = 109.0; camera_bg = 470.0; [track] method = ‘conservative’; pixel_size_μm=0.160; frame interval = 0.00748; search radius = 1; max_blinks = 0; min_IO = 0; scale - 7.0. Trajectories were sorted based on whether they occurred before or after green (561 nm; PAPA) or violet (405 nm; DR) reactivation pulses, and state array analysis (<xref ref-type="bibr" rid="bib28">Heckert et al., 2022b</xref>) was applied to each set of trajectories. For <xref ref-type="fig" rid="fig3">Figure 3C</xref>, reactivation by PAPA and DR for each cell were quantified by calculating the difference in total number of localizations before and after reactivation pulses.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>To derive a measure of error for SMT and SMT-PAPA, we performed bootstrapping analysis on all SMT datasets. For each dataset, a random sample of size n, where n is the total number of cells in the dataset, was drawn 100 times. The mean and standard deviation (stdev) from this analysis is reported.</p><p>Two-tailed p-values were calculated based on a normal distribution (Scipy function, scipy.stats.norm.sf) with mean equal to the difference between sample means and variance equal to the sum of the variances from bootstrap sampling (for SMT and SMT-PAPA) or biological replicates (for absolute abundance calculation of molecules from flow cytometry assay). The Šidák correction was applied to correct for multiple hypothesis testing within each experiment.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an inventor of pending patent application (PCT/US2021/062616) related to the use of PAPA as a molecular proximity sensor</p></fn><fn fn-type="COI-statement" id="conf3"><p>is currently an employee of Eikon Therapeutics</p></fn><fn fn-type="COI-statement" id="conf4"><p>is a co-founder of Eikon Therapeutics, Inc and an inventor on a pending patent application (PCT/US2021/062616) related to the use of PAPA as a molecular proximity sensor</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Visualization, Methodology, Writing – review and editing, Performed and analyzed SMT-PAPA experiments</p></fn><fn fn-type="con" id="con3"><p>Resources</p></fn><fn fn-type="con" id="con4"><p>Resources, Software</p></fn><fn fn-type="con" id="con5"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92979-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Original western blots included in this study are available in accompanying source data zip files. SMT raw data for Figure 1-3 are accessible through <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.14009060">https://doi.org/10.5281/zenodo.14009060</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Dahal</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Surprising Features of Nuclear Receptor Interaction Networks Revealed by Live Cell Single Molecule Imaging [Data set]</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.14009060</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank all members of the Tjian-Darzacq lab for helpful discussions and suggestions over the years, in particular Claudio Cattaglio for advice on biochemistry experiments and Vinson Fan for suggestions on SMT data analysis. We are grateful to John J Ferrie for aiding with Rosetta modeling as well as both him and Jonathan P Karr for critical reading of the manuscript. We also thank Luke Lavis for providing fluorescent HaloTag ligands, CRL Flow Cytometry Facility for use of their instruments, the QB3 High Throughput Screening Facility for providing access to the Opera Phenix automated confocal microscope. This work was supported by the NIH grant U54-CA231641-01659 (to XD) and the Howard Hughes Medical Institute (to RT). TG was supported by a postdoctoral fellowship from the Jane Coffin Childs for Medical Research. AH was supported by the NIH Stem Cell Biological Engineering predoctoral fellowship T32 GM098218.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amati</surname><given-names>B</given-names></name><name><surname>Brooks</surname><given-names>MW</given-names></name><name><surname>Levy</surname><given-names>N</given-names></name><name><surname>Littlewood</surname><given-names>TD</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Land</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Oncogenic activity of the c-Myc protein requires dimerization with Max</article-title><source>Cell</source><volume>72</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90663-b</pub-id><pub-id pub-id-type="pmid">8425220</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayer</surname><given-names>DE</given-names></name><name><surname>Kretzner</surname><given-names>L</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Mad: a heterodimeric partner for max that antagonizes myc transcriptional activity</article-title><source>Cell</source><volume>72</volume><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90661-9</pub-id><pub-id pub-id-type="pmid">8425218</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudino</surname><given-names>TA</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The Max network gone mad</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.3.691-702.2001</pub-id><pub-id pub-id-type="pmid">11154257</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boka</surname><given-names>AP</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Mir</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-molecule tracking technologies for quantifying the dynamics of gene regulation in cells, tissue and embryos</article-title><source>Development</source><volume>148</volume><elocation-id>dev199744</elocation-id><pub-id pub-id-type="doi">10.1242/dev.199744</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>C</given-names></name><name><surname>Dittrich</surname><given-names>O</given-names></name><name><surname>Kiermaier</surname><given-names>A</given-names></name><name><surname>Dohmann</surname><given-names>K</given-names></name><name><surname>Menkel</surname><given-names>A</given-names></name><name><surname>Eilers</surname><given-names>M</given-names></name><name><surname>Lüscher</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of cyclin D2 gene expression by the myc/max/mad network: myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter</article-title><source>Genes &amp; Development</source><volume>15</volume><fpage>2042</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1101/gad.907901</pub-id><pub-id pub-id-type="pmid">11511535</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourguet</surname><given-names>W</given-names></name><name><surname>Vivat</surname><given-names>V</given-names></name><name><surname>Wurtz</surname><given-names>JM</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name><name><surname>Moras</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains</article-title><source>Molecular Cell</source><volume>5</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(00)80424-4</pub-id><pub-id pub-id-type="pmid">10882070</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabender</surname><given-names>J</given-names></name><name><surname>Metzger</surname><given-names>R</given-names></name><name><surname>Salonga</surname><given-names>D</given-names></name><name><surname>Danenberg</surname><given-names>KD</given-names></name><name><surname>Danenberg</surname><given-names>PV</given-names></name><name><surname>Hölscher</surname><given-names>AH</given-names></name><name><surname>Schneider</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis</article-title><source>Carcinogenesis</source><volume>26</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi006</pub-id><pub-id pub-id-type="pmid">15618235</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazda</surname><given-names>P</given-names></name><name><surname>Szekeres</surname><given-names>T</given-names></name><name><surname>Bravics</surname><given-names>B</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Live-cell fluorescence correlation spectroscopy dissects the role of coregulator exchange and chromatin binding in retinoic acid receptor mobility</article-title><source>Journal of Cell Science</source><volume>124</volume><fpage>3631</fpage><lpage>3642</lpage><pub-id pub-id-type="doi">10.1242/jcs.086082</pub-id><pub-id pub-id-type="pmid">22045737</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazda</surname><given-names>P</given-names></name><name><surname>Krieger</surname><given-names>J</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Jonas</surname><given-names>D</given-names></name><name><surname>Szekeres</surname><given-names>T</given-names></name><name><surname>Langowski</surname><given-names>J</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ligand binding shifts highly mobile retinoid X receptor to the chromatin-bound state in a coactivator-dependent manner, as revealed by single-cell imaging</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>1234</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1128/MCB.01097-13</pub-id><pub-id pub-id-type="pmid">24449763</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bwayi</surname><given-names>MN</given-names></name><name><surname>Garcia-Maldonado</surname><given-names>E</given-names></name><name><surname>Chai</surname><given-names>SC</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Chodankar</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>AD</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Annu</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Seetharaman</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Buchman</surname><given-names>CD</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Molecular basis of crosstalk in nuclear receptors: heterodimerization between PXR and CAR and the implication in gene regulation</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>3254</fpage><lpage>3275</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac133</pub-id><pub-id pub-id-type="pmid">35212371</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattoglio</surname><given-names>C</given-names></name><name><surname>Pustova</surname><given-names>I</given-names></name><name><surname>Walther</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>JJ</given-names></name><name><surname>Hantsche-Grininger</surname><given-names>M</given-names></name><name><surname>Inouye</surname><given-names>CJ</given-names></name><name><surname>Hossain</surname><given-names>MJ</given-names></name><name><surname>Dailey</surname><given-names>GM</given-names></name><name><surname>Ellenberg</surname><given-names>J</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Hansen</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Determining cellular CTCF and cohesin abundances to constrain 3D genome models</article-title><source>eLife</source><volume>8</volume><elocation-id>e40164</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.40164</pub-id><pub-id pub-id-type="pmid">31205001</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>LSA</given-names></name><name><surname>Wells</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cross-talk between PPARs and the partners of RXR: a molecular perspective</article-title><source>PPAR Research</source><volume>2009</volume><elocation-id>925309</elocation-id><pub-id pub-id-type="doi">10.1155/2009/925309</pub-id><pub-id pub-id-type="pmid">20052392</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Piekos</surname><given-names>SC</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>XB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A transcriptional regulatory network containing nuclear receptors and long noncoding rnas controls basal and drug-induced expression of cytochrome P450s in HepaRG cells</article-title><source>Molecular Pharmacology</source><volume>94</volume><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1124/mol.118.112235</pub-id><pub-id pub-id-type="pmid">29691280</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins-Racie</surname><given-names>LA</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Arai</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Majumdar</surname><given-names>MK</given-names></name><name><surname>Nagpal</surname><given-names>S</given-names></name><name><surname>Mounts</surname><given-names>WM</given-names></name><name><surname>Dorner</surname><given-names>AJ</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name><name><surname>LaVallie</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis</article-title><source>Osteoarthritis and Cartilage</source><volume>17</volume><fpage>832</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2008.12.011</pub-id><pub-id pub-id-type="pmid">19217805</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concordet</surname><given-names>JP</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W242</fpage><lpage>W245</lpage><pub-id pub-id-type="doi">10.1093/nar/gky354</pub-id><pub-id pub-id-type="pmid">29762716</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahal</surname><given-names>L</given-names></name><name><surname>Walther</surname><given-names>N</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name><name><surname>Graham</surname><given-names>TGW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Single-molecule tracking (SMT): a window into live-cell transcription biochemistry</article-title><source>Biochemical Society Transactions</source><volume>51</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1042/BST20221242</pub-id><pub-id pub-id-type="pmid">36876879</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elf</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>GW</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Probing transcription factor dynamics at the single-molecule level in a living cell</article-title><source>Science</source><volume>316</volume><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1126/science.1141967</pub-id><pub-id pub-id-type="pmid">17525339</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nuclear receptors, rxr, and the big bang</article-title><source>Cell</source><volume>157</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.012</pub-id><pub-id pub-id-type="pmid">24679540</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadel</surname><given-names>L</given-names></name><name><surname>Rehó</surname><given-names>B</given-names></name><name><surname>Volkó</surname><given-names>J</given-names></name><name><surname>Bojcsuk</surname><given-names>D</given-names></name><name><surname>Kolostyák</surname><given-names>Z</given-names></name><name><surname>Nagy</surname><given-names>G</given-names></name><name><surname>Müller</surname><given-names>G</given-names></name><name><surname>Simandi</surname><given-names>Z</given-names></name><name><surname>Hegedüs</surname><given-names>É</given-names></name><name><surname>Szabó</surname><given-names>G</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Agonist binding directs dynamic competition among nuclear receptors for heterodimerization with retinoid X receptor</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>10045</fpage><lpage>10061</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.011614</pub-id><pub-id pub-id-type="pmid">32513869</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frigo</surname><given-names>DE</given-names></name><name><surname>Bondesson</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nuclear receptors: from molecular mechanisms to therapeutics</article-title><source>Essays in Biochemistry</source><volume>65</volume><elocation-id>e00222</elocation-id><pub-id pub-id-type="doi">10.1210/er.2018-00222</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>MB</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Hariharan</surname><given-names>M</given-names></name><name><surname>Landt</surname><given-names>SG</given-names></name><name><surname>Yan</surname><given-names>K-K</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Mu</surname><given-names>XJ</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Rozowsky</surname><given-names>J</given-names></name><name><surname>Alexander</surname><given-names>R</given-names></name><name><surname>Min</surname><given-names>R</given-names></name><name><surname>Alves</surname><given-names>P</given-names></name><name><surname>Abyzov</surname><given-names>A</given-names></name><name><surname>Addleman</surname><given-names>N</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Boyle</surname><given-names>AP</given-names></name><name><surname>Cayting</surname><given-names>P</given-names></name><name><surname>Charos</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>DZ</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Clarke</surname><given-names>D</given-names></name><name><surname>Eastman</surname><given-names>C</given-names></name><name><surname>Euskirchen</surname><given-names>G</given-names></name><name><surname>Frietze</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Gertz</surname><given-names>J</given-names></name><name><surname>Grubert</surname><given-names>F</given-names></name><name><surname>Harmanci</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>P</given-names></name><name><surname>Kasowski</surname><given-names>M</given-names></name><name><surname>Lacroute</surname><given-names>P</given-names></name><name><surname>Leng</surname><given-names>JJ</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Monahan</surname><given-names>H</given-names></name><name><surname>O’Geen</surname><given-names>H</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Partridge</surname><given-names>EC</given-names></name><name><surname>Patacsil</surname><given-names>D</given-names></name><name><surname>Pauli</surname><given-names>F</given-names></name><name><surname>Raha</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>L</given-names></name><name><surname>Reddy</surname><given-names>TE</given-names></name><name><surname>Reed</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Slifer</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yip</surname><given-names>KY</given-names></name><name><surname>Zilberman-Schapira</surname><given-names>G</given-names></name><name><surname>Batzoglou</surname><given-names>S</given-names></name><name><surname>Sidow</surname><given-names>A</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Weissman</surname><given-names>SM</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Architecture of the human regulatory network derived from ENCODE data</article-title><source>Nature</source><volume>489</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/nature11245</pub-id><pub-id pub-id-type="pmid">22955619</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>TGW</given-names></name><name><surname>Ferrie</surname><given-names>JJ</given-names></name><name><surname>Dailey</surname><given-names>GM</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Detecting molecular interactions in live-cell single-molecule imaging with proximity-assisted photoactivation (PAPA)</article-title><source>eLife</source><volume>11</volume><elocation-id>e76870</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.76870</pub-id><pub-id pub-id-type="pmid">35976226</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>TGW</given-names></name><name><surname>Dugast-Darzacq</surname><given-names>C</given-names></name><name><surname>Dailey</surname><given-names>GM</given-names></name><name><surname>Weng</surname><given-names>B</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Single-molecule live imaging of subunit interactions and exchange within cellular regulatory complexes</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.06.25.600644</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinberg</surname><given-names>AV</given-names></name><name><surname>Hu</surname><given-names>C-D</given-names></name><name><surname>Kerppola</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>4294</fpage><lpage>4308</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.10.4294-4308.2004</pub-id><pub-id pub-id-type="pmid">15121849</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>AS</given-names></name><name><surname>Pustova</surname><given-names>I</given-names></name><name><surname>Cattoglio</surname><given-names>C</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CTCF and cohesin regulate chromatin loop stability with distinct dynamics</article-title><source>eLife</source><volume>6</volume><elocation-id>e25776</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.25776</pub-id><pub-id pub-id-type="pmid">28467304</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>AS</given-names></name><name><surname>Woringer</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>JB</given-names></name><name><surname>Lavis</surname><given-names>LD</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Robust model-based analysis of single-particle tracking experiments with Spot-On</article-title><source>eLife</source><volume>7</volume><elocation-id>e33125</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33125</pub-id><pub-id pub-id-type="pmid">29300163</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Heckert</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>V</given-names></name><name><surname>Yeo</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2022">2022a</year><data-title>saspt</data-title><version designator="ad0fa30">ad0fa30</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/alecheckert/saspt">https://github.com/alecheckert/saspt</ext-link></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckert</surname><given-names>A</given-names></name><name><surname>Dahal</surname><given-names>L</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Recovering mixtures of fast-diffusing states from short single-particle trajectories</article-title><source>eLife</source><volume>11</volume><elocation-id>e70169</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.70169</pub-id><pub-id pub-id-type="pmid">36066004</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Heckert</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Quot: A simple single molecule tracking pipeline with A graphic user interface for quality control</data-title><version designator="1b9051e">1b9051e</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/alecheckert/quot">https://github.com/alecheckert/quot</ext-link></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilemann</surname><given-names>M</given-names></name><name><surname>van de Linde</surname><given-names>S</given-names></name><name><surname>Schüttpelz</surname><given-names>M</given-names></name><name><surname>Kasper</surname><given-names>R</given-names></name><name><surname>Seefeldt</surname><given-names>B</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Tinnefeld</surname><given-names>P</given-names></name><name><surname>Sauer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes</article-title><source>Angewandte Chemie</source><volume>47</volume><fpage>6172</fpage><lpage>6176</lpage><pub-id pub-id-type="doi">10.1002/anie.200802376</pub-id><pub-id pub-id-type="pmid">18646237</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>LM</given-names></name><name><surname>Garcha</surname><given-names>K</given-names></name><name><surname>Karamboulas</surname><given-names>K</given-names></name><name><surname>Cowan</surname><given-names>MF</given-names></name><name><surname>Drysdale</surname><given-names>LM</given-names></name><name><surname>Horton</surname><given-names>WA</given-names></name><name><surname>Underhill</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>BMP action in skeletogenesis involves attenuation of retinoid signaling</article-title><source>The Journal of Cell Biology</source><volume>174</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1083/jcb.200604150</pub-id><pub-id pub-id-type="pmid">16818722</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurlin</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The MAX-interacting transcription factor network</article-title><source>Seminars in Cancer Biology</source><volume>16</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2006.07.009</pub-id><pub-id pub-id-type="pmid">16908182</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Yahagi</surname><given-names>N</given-names></name><name><surname>Amemiya-Kudo</surname><given-names>M</given-names></name><name><surname>Matsuzaka</surname><given-names>T</given-names></name><name><surname>Nakakuki</surname><given-names>M</given-names></name><name><surname>Yatoh</surname><given-names>S</given-names></name><name><surname>Iizuka</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>S</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Sone</surname><given-names>H</given-names></name><name><surname>Gotoda</surname><given-names>T</given-names></name><name><surname>Osuga</surname><given-names>J</given-names></name><name><surname>Ishibashi</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling</article-title><source>Molecular Endocrinology</source><volume>17</volume><fpage>1255</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1210/me.2002-0191</pub-id><pub-id pub-id-type="pmid">12730332</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>A</given-names></name><name><surname>Nawaz</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Nuclear hormone receptor degradation and gene transcription: an update</article-title><source>IUBMB Life</source><volume>57</volume><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1080/15216540500147163</pub-id><pub-id pub-id-type="pmid">16081369</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klumpe</surname><given-names>HE</given-names></name><name><surname>Garcia-Ojalvo</surname><given-names>J</given-names></name><name><surname>Elowitz</surname><given-names>MB</given-names></name><name><surname>Antebi</surname><given-names>YE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The computational capabilities of many-to-many protein interaction networks</article-title><source>Cell Systems</source><volume>14</volume><fpage>430</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2023.05.001</pub-id><pub-id pub-id-type="pmid">37348461</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopf</surname><given-names>E</given-names></name><name><surname>Plassat</surname><given-names>JL</given-names></name><name><surname>Vivat</surname><given-names>V</given-names></name><name><surname>de Thé</surname><given-names>H</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Rochette-Egly</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>33280</fpage><lpage>33288</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002840200</pub-id><pub-id pub-id-type="pmid">10869350</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>MD</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pan-cancer analyses of the nuclear receptor superfamily</article-title><source>Nuclear Receptor Research</source><volume>2</volume><elocation-id>101182</elocation-id><pub-id pub-id-type="doi">10.11131/2015/101182</pub-id><pub-id pub-id-type="pmid">27200367</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Los</surname><given-names>GV</given-names></name><name><surname>Encell</surname><given-names>LP</given-names></name><name><surname>McDougall</surname><given-names>MG</given-names></name><name><surname>Hartzell</surname><given-names>DD</given-names></name><name><surname>Karassina</surname><given-names>N</given-names></name><name><surname>Zimprich</surname><given-names>C</given-names></name><name><surname>Wood</surname><given-names>MG</given-names></name><name><surname>Learish</surname><given-names>R</given-names></name><name><surname>Ohana</surname><given-names>RF</given-names></name><name><surname>Urh</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Mendez</surname><given-names>J</given-names></name><name><surname>Zimmerman</surname><given-names>K</given-names></name><name><surname>Otto</surname><given-names>P</given-names></name><name><surname>Vidugiris</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Darzins</surname><given-names>A</given-names></name><name><surname>Klaubert</surname><given-names>DH</given-names></name><name><surname>Bulleit</surname><given-names>RF</given-names></name><name><surname>Wood</surname><given-names>KV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Halotag: a novel protein labeling technology for cell imaging and protein analysis</article-title><source>ACS Chemical Biology</source><volume>3</volume><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1021/cb800025k</pub-id><pub-id pub-id-type="pmid">18533659</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>KG</given-names></name><name><surname>Kolla</surname><given-names>S</given-names></name><name><surname>Aguirre</surname><given-names>JD</given-names></name><name><surname>Garshott</surname><given-names>DM</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Haakonsen</surname><given-names>DL</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Kater</surname><given-names>L</given-names></name><name><surname>Kempf</surname><given-names>G</given-names></name><name><surname>Martínez-González</surname><given-names>B</given-names></name><name><surname>Akopian</surname><given-names>D</given-names></name><name><surname>See</surname><given-names>SK</given-names></name><name><surname>Thomä</surname><given-names>NH</given-names></name><name><surname>Rapé</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Orphan quality control shapes network dynamics and gene expression</article-title><source>Cell</source><volume>186</volume><fpage>3460</fpage><lpage>3475</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.06.015</pub-id><pub-id pub-id-type="pmid">37478862</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsusue</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>A</given-names></name><name><surname>Yamano</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR</article-title><source>Molecular and Cellular Endocrinology</source><volume>256</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2006.05.005</pub-id><pub-id pub-id-type="pmid">16806672</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Combinatorial control of gene expression by nuclear receptors and coregulators</article-title><source>Cell</source><volume>108</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00641-4</pub-id><pub-id pub-id-type="pmid">11909518</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McSwiggen</surname><given-names>DT</given-names></name><name><surname>Hansen</surname><given-names>AS</given-names></name><name><surname>Teves</surname><given-names>SS</given-names></name><name><surname>Marie-Nelly</surname><given-names>H</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Heckert</surname><given-names>AB</given-names></name><name><surname>Umemoto</surname><given-names>KK</given-names></name><name><surname>Dugast-Darzacq</surname><given-names>C</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evidence for DNA-mediated nuclear compartmentalization distinct from phase separation</article-title><source>eLife</source><volume>8</volume><elocation-id>e47098</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.47098</pub-id><pub-id pub-id-type="pmid">31038454</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McSwiggen</surname><given-names>DT</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Puig</surname><given-names>SA</given-names></name><name><surname>Akella</surname><given-names>LB</given-names></name><name><surname>Berman</surname><given-names>R</given-names></name><name><surname>Bretan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name><name><surname>Ford</surname><given-names>K</given-names></name><name><surname>Godbey</surname><given-names>R</given-names></name><name><surname>Gonzalez</surname><given-names>E</given-names></name><name><surname>Hanuka</surname><given-names>A</given-names></name><name><surname>Heckert</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JJ</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name><name><surname>Kelso</surname><given-names>R</given-names></name><name><surname>Klammer</surname><given-names>A</given-names></name><name><surname>Krishnamurthy</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Margolin</surname><given-names>B</given-names></name><name><surname>McNamara</surname><given-names>P</given-names></name><name><surname>Meyer</surname><given-names>L</given-names></name><name><surname>Pierce</surname><given-names>SE</given-names></name><name><surname>Sule</surname><given-names>A</given-names></name><name><surname>Stashko</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Beck</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms</article-title><source>eLife</source><elocation-id>e1832</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.93183.2</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Nandagopal</surname><given-names>N</given-names></name><name><surname>Terrio</surname><given-names>A</given-names></name><name><surname>Vicente</surname><given-names>FZ</given-names></name><name><surname>Jambhekar</surname><given-names>A</given-names></name><name><surname>Lahav</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Signal integration by a bhlh circuit enables fate choice in neural stem cells</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.10.10.511605</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osburn</surname><given-names>DL</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Seidel</surname><given-names>HM</given-names></name><name><surname>Schulman</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>4909</fpage><lpage>4918</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.15.4909-4918.2001</pub-id><pub-id pub-id-type="pmid">11438648</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Tsai</surname><given-names>C-J</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>How do transcription factors select specific binding sites in the genome?</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>16</volume><fpage>1118</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/nsmb1109-1118</pub-id><pub-id pub-id-type="pmid">19888307</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatheodorou</surname><given-names>I</given-names></name><name><surname>Moreno</surname><given-names>P</given-names></name><name><surname>Manning</surname><given-names>J</given-names></name><name><surname>Fuentes</surname><given-names>AMP</given-names></name><name><surname>George</surname><given-names>N</given-names></name><name><surname>Fexova</surname><given-names>S</given-names></name><name><surname>Fonseca</surname><given-names>NA</given-names></name><name><surname>Füllgrabe</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Huerta</surname><given-names>L</given-names></name><name><surname>Iqbal</surname><given-names>H</given-names></name><name><surname>Jianu</surname><given-names>M</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Jarnuczak</surname><given-names>AF</given-names></name><name><surname>Jupp</surname><given-names>S</given-names></name><name><surname>Marioni</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Petryszak</surname><given-names>R</given-names></name><name><surname>Prada Medina</surname><given-names>CA</given-names></name><name><surname>Talavera-López</surname><given-names>C</given-names></name><name><surname>Teichmann</surname><given-names>S</given-names></name><name><surname>Vizcaino</surname><given-names>JA</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Expression Atlas update: from tissues to single cells</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D77</fpage><lpage>D83</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz947</pub-id><pub-id pub-id-type="pmid">31665515</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>García-Seisdedos</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>George</surname><given-names>N</given-names></name><name><surname>Moreno</surname><given-names>P</given-names></name><name><surname>Papatheodorou</surname><given-names>I</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Integrated view of baseline protein expression in human tissues</article-title><source>Journal of Proteome Research</source><volume>22</volume><fpage>729</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.2c00406</pub-id><pub-id pub-id-type="pmid">36577097</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Puig-Barbé</surname><given-names>A</given-names></name><name><surname>Nirello</surname><given-names>VD</given-names></name><name><surname>Azami</surname><given-names>S</given-names></name><name><surname>Edgar</surname><given-names>BA</given-names></name><name><surname>Varga-Weisz</surname><given-names>P</given-names></name><name><surname>Korzelius</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Homo- and Heterodimerization of bHLH Transcription Factors Balance Stemness and Bipotential Differentiation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/685347</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastinejad</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Khorasanizadeh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>1045</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.5.1045</pub-id><pub-id pub-id-type="pmid">10698945</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastinejad</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Retinoic acid receptor structures: the journey from single domains to full-length complex</article-title><source>Journal of Molecular Endocrinology</source><volume>69</volume><fpage>T25</fpage><lpage>T36</lpage><pub-id pub-id-type="doi">10.1530/JME-22-0113</pub-id><pub-id pub-id-type="pmid">36069789</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehó</surname><given-names>B</given-names></name><name><surname>Lau</surname><given-names>L</given-names></name><name><surname>Mocsár</surname><given-names>G</given-names></name><name><surname>Müller</surname><given-names>G</given-names></name><name><surname>Fadel</surname><given-names>L</given-names></name><name><surname>Brázda</surname><given-names>P</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Simultaneous mapping of molecular proximity and comobility reveals agonist-enhanced dimerization and dna binding of nuclear receptors</article-title><source>Analytical Chemistry</source><volume>92</volume><fpage>2207</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.9b04902</pub-id><pub-id pub-id-type="pmid">31870146</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehó</surname><given-names>B</given-names></name><name><surname>Fadel</surname><given-names>L</given-names></name><name><surname>Brazda</surname><given-names>P</given-names></name><name><surname>Benziane</surname><given-names>A</given-names></name><name><surname>Hegedüs</surname><given-names>É</given-names></name><name><surname>Sen</surname><given-names>P</given-names></name><name><surname>Gadella</surname><given-names>TWJ</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding</article-title><source>The Journal of Biological Chemistry</source><volume>299</volume><elocation-id>102896</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.102896</pub-id><pub-id pub-id-type="pmid">36639026</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reményi</surname><given-names>A</given-names></name><name><surname>Schöler</surname><given-names>HR</given-names></name><name><surname>Wilmanns</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Combinatorial control of gene expression</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>11</volume><fpage>812</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1038/nsmb820</pub-id><pub-id pub-id-type="pmid">15332082</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shringari</surname><given-names>SR</given-names></name><name><surname>Giannakoulias</surname><given-names>S</given-names></name><name><surname>Ferrie</surname><given-names>JJ</given-names></name><name><surname>Petersson</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rosetta custom score functions accurately predict ΔΔ    <italic>G</italic>    of mutations at protein–protein interfaces using machine learning</article-title><source>Chemical Communications</source><volume>56</volume><fpage>6774</fpage><lpage>6777</lpage><pub-id pub-id-type="doi">10.1039/D0CC01959C</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thul</surname><given-names>PJ</given-names></name><name><surname>Åkesson</surname><given-names>L</given-names></name><name><surname>Wiking</surname><given-names>M</given-names></name><name><surname>Mahdessian</surname><given-names>D</given-names></name><name><surname>Geladaki</surname><given-names>A</given-names></name><name><surname>Ait Blal</surname><given-names>H</given-names></name><name><surname>Alm</surname><given-names>T</given-names></name><name><surname>Asplund</surname><given-names>A</given-names></name><name><surname>Björk</surname><given-names>L</given-names></name><name><surname>Breckels</surname><given-names>LM</given-names></name><name><surname>Bäckström</surname><given-names>A</given-names></name><name><surname>Danielsson</surname><given-names>F</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Fall</surname><given-names>J</given-names></name><name><surname>Gatto</surname><given-names>L</given-names></name><name><surname>Gnann</surname><given-names>C</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Hjelmare</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Mulvey</surname><given-names>CM</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><name><surname>Schutten</surname><given-names>R</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Sivertsson</surname><given-names>Å</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Skogs</surname><given-names>M</given-names></name><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Sullivan</surname><given-names>DP</given-names></name><name><surname>Tegel</surname><given-names>H</given-names></name><name><surname>Winsnes</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Lilley</surname><given-names>KS</given-names></name><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A subcellular map of the human proteome</article-title><source>Science</source><volume>356</volume><elocation-id>eaal3321</elocation-id><pub-id pub-id-type="doi">10.1126/science.aal3321</pub-id><pub-id pub-id-type="pmid">28495876</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>M</given-names></name><name><surname>Imamoto</surname><given-names>N</given-names></name><name><surname>Sakata-Sogawa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Highly inclined thin illumination enables clear single-molecule imaging in cells</article-title><source>Nature Methods</source><volume>5</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/nmeth1171</pub-id><pub-id pub-id-type="pmid">18176568</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>JM</given-names></name><name><surname>Aguirre</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>Y-D</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Focht</surname><given-names>V</given-names></name><name><surname>Kater</surname><given-names>L</given-names></name><name><surname>Kempf</surname><given-names>G</given-names></name><name><surname>Sandoval</surname><given-names>B</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Rutter</surname><given-names>JC</given-names></name><name><surname>Galli</surname><given-names>P</given-names></name><name><surname>Sandate</surname><given-names>CR</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Zou</surname><given-names>C</given-names></name><name><surname>Donovan</surname><given-names>KA</given-names></name><name><surname>Lumpkin</surname><given-names>RJ</given-names></name><name><surname>Cavadini</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>PMC</given-names></name><name><surname>Sievers</surname><given-names>Q</given-names></name><name><surname>Hatton</surname><given-names>C</given-names></name><name><surname>Ener</surname><given-names>E</given-names></name><name><surname>Regalado</surname><given-names>BD</given-names></name><name><surname>Sperling</surname><given-names>MT</given-names></name><name><surname>Słabicki</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Zon</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Miller</surname><given-names>PG</given-names></name><name><surname>Belizaire</surname><given-names>R</given-names></name><name><surname>Sperling</surname><given-names>AS</given-names></name><name><surname>Fischer</surname><given-names>ES</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Thomä</surname><given-names>NH</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability</article-title><source>Molecular Cell</source><volume>83</volume><fpage>2753</fpage><lpage>2767</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.06.028</pub-id><pub-id pub-id-type="pmid">37478846</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallström</surname><given-names>BM</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Sivertsson</surname><given-names>Å</given-names></name><name><surname>Kampf</surname><given-names>C</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Asplund</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>I</given-names></name><name><surname>Edlund</surname><given-names>K</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Navani</surname><given-names>S</given-names></name><name><surname>Szigyarto</surname><given-names>CA-K</given-names></name><name><surname>Odeberg</surname><given-names>J</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Takanen</surname><given-names>JO</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Alm</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>P-H</given-names></name><name><surname>Berling</surname><given-names>H</given-names></name><name><surname>Tegel</surname><given-names>H</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Hamsten</surname><given-names>M</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Forsberg</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>F</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>von Heijne</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Proteomics: tissue-based map of the human proteome</article-title><source>Science</source><volume>347</volume><elocation-id>1260419</elocation-id><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>ZQ</given-names></name><name><surname>Ota</surname><given-names>S</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><name><surname>Hurlin</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mnt-max to myc-max complex switching regulates cell cycle entry</article-title><source>The Journal of Cell Biology</source><volume>169</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1083/jcb.200411013</pub-id><pub-id pub-id-type="pmid">15866886</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>N</given-names></name><name><surname>Anantakrishnan</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>TGW</given-names></name><name><surname>Dailey</surname><given-names>GM</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name><name><surname>Darzacq</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Automated live-cell single-molecule tracking in enteroid monolayers reveals transcription factor dynamics probing lineage-determining function</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>114914</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114914</pub-id><pub-id pub-id-type="pmid">39480809</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>YY</given-names></name><name><surname>Ballock</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Peroxisome proliferator activated receptor-gamma (PPARgamma) represses thyroid hormone signaling in growth plate chondrocytes</article-title><source>Bone</source><volume>37</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2005.04.031</pub-id><pub-id pub-id-type="pmid">16023420</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Nanayakkara</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Drummer</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Cueto</surname><given-names>R</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Bottiglieri</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y-F</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>WY</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>ET</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis-associated molecular pattern receptors</article-title><source>Journal of Hematology &amp; Oncology</source><volume>10</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-017-0526-8</pub-id><pub-id pub-id-type="pmid">29065888</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Vitamin D and adipogenesis: new molecular insights</article-title><source>Nutrition Reviews</source><volume>66</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/j.1753-4887.2007.00004.x</pub-id><pub-id pub-id-type="pmid">18254883</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Popov</surname><given-names>N</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Björkholm</surname><given-names>M</given-names></name><name><surname>Gruber</surname><given-names>A</given-names></name><name><surname>Menkel</surname><given-names>AR</given-names></name><name><surname>Henriksson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells</article-title><source>PNAS</source><volume>98</volume><fpage>3826</fpage><lpage>3831</lpage><pub-id pub-id-type="doi">10.1073/pnas.071043198</pub-id><pub-id pub-id-type="pmid">11274400</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Yahagi</surname><given-names>N</given-names></name><name><surname>Amemiya-Kudo</surname><given-names>M</given-names></name><name><surname>Matsuzaka</surname><given-names>T</given-names></name><name><surname>Yatoh</surname><given-names>S</given-names></name><name><surname>Kitamine</surname><given-names>T</given-names></name><name><surname>Okazaki</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>Y</given-names></name><name><surname>Sekiya</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Hasty</surname><given-names>AH</given-names></name><name><surname>Sato</surname><given-names>R</given-names></name><name><surname>Sone</surname><given-names>H</given-names></name><name><surname>Osuga</surname><given-names>JI</given-names></name><name><surname>Ishibashi</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cross-talk between peroxisome proliferator-activated receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARS suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signali</article-title><source>Molecular Endocrinology</source><volume>17</volume><fpage>1255</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1210/me.2002-0190</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Gianni</surname><given-names>M</given-names></name><name><surname>Kopf</surname><given-names>E</given-names></name><name><surname>Honoré</surname><given-names>N</given-names></name><name><surname>Chelbi-Alix</surname><given-names>M</given-names></name><name><surname>Koken</surname><given-names>M</given-names></name><name><surname>Quignon</surname><given-names>F</given-names></name><name><surname>Rochette-Egly</surname><given-names>C</given-names></name><name><surname>de Thé</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins</article-title><source>PNAS</source><volume>96</volume><fpage>14807</fpage><lpage>14812</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.26.14807</pub-id><pub-id pub-id-type="pmid">10611294</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Brief overview of the steps involved in a PAPA-SMT experiment</title><p>A PAPA-SMT (<xref ref-type="bibr" rid="bib22">Graham et al., 2022</xref>) experiment involves several steps (<xref ref-type="fig" rid="fig3">Figure 3A</xref>): (1) A SNAP-tagged target protein is labeled with a ‘receiver’ fluorophore such as JFX650, while a Halo-tagged partner protein is labeled with a ‘sender’ fluorophore such as JFX549. (2) The JFX650 receiver is placed in a dark state by illumination with intense red (639 nm) light. (3) A pulse of green (561 nm) light is used to excite the JFX549 sender, reactivating nearby dark-state JFX650 molecules. Because association of the two proteins brings the sender and receiver together, this step selectively reactivates complexes of the two proteins. (4) After switching off the green light, red light is used to image reactivated receiver molecules. (5) As an internal control, a violet (405 nm) light pulse is used to reactivate the receiver by ‘DR’, independent of proximity with the sender (<xref ref-type="bibr" rid="bib30">Heilemann et al., 2008</xref>). (6) After switching off the violet light, reactivated molecules are again imaged with red light. Steps 3–6 are repeated for multiple rounds, and SMT trajectories occurring after green and violet pulses are analyzed separately using SASPT. Trajectories occurring after a green pulse (PAPA trajectories) are enriched for complexes between the SNAP- and Halo-tagged proteins, while trajectories occurring after a violet pulse (DR trajectories) approximate a random sample from the whole population.</p></sec></app><app id="appendix-2"><title>Appendix 2</title><table-wrap id="app2table1" position="float"><label>Appendix 2—table 1.</label><caption><title>T2NRs expressed in U2OS cells according to the Expression Atlas (<xref ref-type="bibr" rid="bib47">Papatheodorou et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Prakash et al., 2023</xref>) and the Human Protein Atlas Databank (<xref ref-type="bibr" rid="bib56">Thul et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Uhlén et al., 2015</xref>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">TPM (Expression Atlas)</th><th align="left" valign="bottom">TPM (Human Protein Atlas)</th></tr></thead><tbody><tr><td align="left" valign="bottom">RARα (NR1B2)</td><td align="left" valign="bottom">43</td><td align="left" valign="bottom">47.1</td></tr><tr><td align="left" valign="bottom">RARβ (NR1B2)</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0.1<break/></td></tr><tr><td align="left" valign="bottom">RARγ (NR1B3)</td><td align="left" valign="bottom">39</td><td align="left" valign="bottom">16.5</td></tr><tr><td align="left" valign="bottom">RXRα (NR2B1)</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">23.4</td></tr><tr><td align="left" valign="bottom">RXRβ (NR2B2)<xref ref-type="table-fn" rid="app2table1fn2">*</xref></td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">5.3</td></tr><tr><td align="left" valign="bottom">RXRγ (NR2B3)</td><td align="left" valign="bottom">n/a</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">THRA (NR1A1)</td><td align="left" valign="bottom">41</td><td align="left" valign="bottom">18.2</td></tr><tr><td align="left" valign="bottom">THRB (NR1A2)</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">3</td></tr><tr><td align="left" valign="bottom">LXRA (NR1H3)</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">6.4</td></tr><tr><td align="left" valign="bottom">LXRB (NR1H2)</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">44.8</td></tr><tr><td align="left" valign="bottom">COUP-TF1 (NR2F2)</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">2.4</td></tr><tr><td align="left" valign="bottom">COUP-TF2 (NR2F2)</td><td align="left" valign="bottom">34</td><td align="left" valign="bottom">39.7</td></tr><tr><td align="left" valign="bottom">VDR (NR1I1)</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">7.3</td></tr><tr><td align="left" valign="bottom">FXR (NR1H4)</td><td align="left" valign="bottom">n/a</td><td align="left" valign="bottom">0.2</td></tr><tr><td align="left" valign="bottom">PPARA</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">7.7</td></tr><tr><td align="left" valign="bottom">PPARD</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom">17.2</td></tr><tr><td align="left" valign="bottom">PPARG</td><td align="left" valign="bottom">7</td><td align="left" valign="bottom">11.4</td></tr><tr><td align="left" valign="bottom">NURR (NRA42)</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">PXR (NR1I2)</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">CAR (NR1I3)</td><td align="left" valign="bottom">26</td><td align="left" valign="bottom">0.3</td></tr></tbody></table><table-wrap-foot><fn><p>TPM = transcripts per kilobase million, TPM values reported by the European Bioinformatics Institute Expression Atlas (ebi.ac.uk) and Human Protein Data Bank (proteinatlas.org) for Type II nuclear receptors (T2NRs) expression in U2OS cells.</p></fn><fn id="app2table1fn2"><label>*</label><p>Note: We also observe expression of RXRβ in U2OS cells when probed with RXR antibody specific to the C-terminal epitope (Proteintech, #212181AP) in western blot (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="app2table2" position="float"><label>Appendix 2—table 2.</label><caption><title>Plasmid constructs used for co-immunoprecipitation and to make stable cell lines.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Promoter</th><th align="left" valign="bottom">Gene product</th><th align="left" valign="bottom">Short name in the paper</th><th align="left" valign="bottom">Appeared in</th></tr></thead><tbody><tr><td align="left" valign="bottom">PB EF1α RARα-GDGAGLIN-Halo-3xFLAG IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RARα C-terminally fused with 3xFLAG-Halo tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RARα-Halo</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2A–C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">PB EF1α V5-Halo-GDGAGLIN-RXRα IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RXRα N-terminally fused with V5-Halo tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">Halo-RXRα</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2A–C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref></td></tr><tr><td align="left" valign="bottom">PB EF1αRARα_M379R_T386R-GDGAGLIN-Halo-3xF IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RAR<sup>RR</sup>α C-terminally fused with 3xFLAG-Halo tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RARα<sup>RR</sup>-Halo</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref></td></tr><tr><td align="left" valign="bottom">PB Puro EF1α-RARα-GDGAGLIN-3xFLAG</td><td align="left" valign="bottom">EF1a</td><td align="left" valign="bottom">RARα C-terminally fused with 3xFLAG tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RARα</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref></td></tr><tr><td align="left" valign="bottom">PB EF1a V5-RXRα IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RXRα N-terminally fused with V5 tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RXRα</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref></td></tr><tr><td align="left" valign="bottom">PB EF1α ExMCS-GDGAGLIN-SNAPf-3xFLAG IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">SNAPf-3xFLAG tag with a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">SNAP</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2D–F</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–D</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref></td></tr><tr><td align="left" valign="bottom">PB EF1α RARα-GDGAGLIN-SNAPf-3xFLAG IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RARα C-terminally fused with 3xFLAG-SNAPf tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RARα-SNAP</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2D–F</xref>, <xref ref-type="fig" rid="fig3">Figure 3B and C</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–D</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref></td></tr><tr><td align="left" valign="bottom">PB EF1α RAR<sup>RR</sup>α -GDGAGLIN-SNAPf-3xFLAG IRES Puro</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RAR<sup>RR</sup>α C-terminally fused with 3xFLAG-SNAPf tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">RARα<sup>RR</sup>-SNAP</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2D–F</xref>, <xref ref-type="fig" rid="fig3">Figure 3B and C</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–D</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref></td></tr><tr><td align="left" valign="bottom">PB EF1α V5-SNAPf-GDGAGLIN-RXRα IRES Neo</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">RXRα N-terminally fused with V5-SNAPf tag through a short peptide linker sequence (GDGAGLIN)</td><td align="left" valign="bottom">SNAP-RXRα</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2D–F</xref>, <xref ref-type="fig" rid="fig3">Figure 3B and C</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–D</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref></td></tr><tr><td align="left" valign="bottom">PB PGK Puro EF1α SNAPf- 3xNLS</td><td align="left" valign="bottom">EF1α</td><td align="left" valign="bottom">SNAPf - 3xNLS linked through a short linker peptide sequence (GDGAGLIN)</td><td align="left" valign="bottom">SNAP-NLS</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref></td></tr></tbody></table></table-wrap><table-wrap id="app2table3" position="float"><label>Appendix 2—table 3.</label><caption><title>Summary of single-molecule tracking (SMT) analysis for all conditions.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom"><italic>f</italic><sub>bound</sub></th><th align="left" valign="bottom">stdev</th><th align="left" valign="bottom">Num of cells</th><th align="left" valign="bottom">Trajs<xref ref-type="table-fn" rid="app2table3fn1">*</xref></th><th align="left" valign="bottom">Appeared in</th></tr></thead><tbody><tr><td align="left" valign="bottom">H2B-Halo</td><td align="char" char="." valign="bottom">75.5</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">108955</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref></td></tr><tr><td align="left" valign="bottom">Halo-3xNLS</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">67555</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156</td><td align="char" char="." valign="bottom">49</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">100148</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C and F</xref> <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A and B</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c239</td><td align="char" char="." valign="bottom">47</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">42405</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c258</td><td align="char" char="." valign="bottom">53</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">74195</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.c10</td><td align="char" char="." valign="bottom">36</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">29690</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D6</td><td align="char" char="." valign="bottom">36</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">24886</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C and F</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D9</td><td align="char" char="." valign="bottom">42</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">30594</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/o atRA</td><td align="char" char="." valign="bottom">53</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">14679</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/ 1 nM atRA</td><td align="char" char="." valign="bottom">54</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">15096</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/ 100 nM atRA</td><td align="char" char="." valign="bottom">53</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">13795</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D6 w/o atRA</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">17495</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.D6 w/ 1 nM atRA</td><td align="char" char="." valign="bottom">31</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">17358</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.D6 w/ 100 nM atRA</td><td align="char" char="." valign="bottom">31</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">18899</td><td align="left" valign="bottom"> <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">OE RARα-Halo</td><td align="char" char="." valign="bottom">27</td><td align="char" char="." valign="bottom">0.72</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">21997</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B and C</xref></td></tr><tr><td align="left" valign="bottom">OE Halo-RXRα</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">62767</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B and C</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ SNAP</td><td align="char" char="." valign="bottom">47</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">35396</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ RARα<sup>RR</sup> SNAP</td><td align="char" char="." valign="bottom">43</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">43</td><td align="char" char="." valign="bottom">46435</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ SNAP-RXRα</td><td align="char" char="." valign="bottom">49</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">41411</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ RARα-SNAP</td><td align="char" char="." valign="bottom">29</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">46</td><td align="char" char="." valign="bottom">34378</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ SNAP</td><td align="char" char="." valign="bottom">38</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">26031</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ RARα<sup>RR</sup>-SNAP</td><td align="char" char="." valign="bottom">35</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">24137</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ SNAP-RXRα</td><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">24910</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ RARα-SNAP</td><td align="char" char="." valign="bottom">56</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">25373</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A nd B</xref></td></tr></tbody></table><table-wrap-foot><fn id="app2table3fn1"><label>*</label><p>Trajs refers to total number of trajectories of the whole set.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app2table4" position="float"><label>Appendix 2—table 4.</label><caption><title>Number of molecules estimated according to the previously published protocol (<xref ref-type="bibr" rid="bib11">Cattoglio et al., 2019</xref>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Est.# molecules</th><th align="left" valign="bottom">Appeared in</th></tr></thead><tbody><tr><td align="left" valign="bottom">Negative control</td><td align="left" valign="bottom">0 (fixed)</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">CTCF</td><td align="left" valign="bottom">109,800 (standard)</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156</td><td align="left" valign="bottom">57,024±7048</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 1) and <xref ref-type="fig" rid="fig2">Figure 2E</xref><break/><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c239</td><td align="left" valign="bottom">51,596±6144</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 2)</td></tr><tr><td align="left" valign="bottom">I RARα.c258</td><td align="left" valign="bottom">56,516±5260</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 3)</td></tr><tr><td align="left" valign="bottom">I RXRα.c10</td><td align="left" valign="bottom">53,548±4042</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 1)</td></tr><tr><td align="left" valign="bottom">I RXRα.D6</td><td align="left" valign="bottom">50,702±5616</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 2) and <xref ref-type="fig" rid="fig2">Figure 2E</xref><break/><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D9</td><td align="left" valign="bottom">50,946±5645</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref> (replicate 3)</td></tr><tr><td align="left" valign="bottom">I RARα (average)</td><td align="left" valign="bottom">55,045±2997</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα (average)</td><td align="left" valign="bottom">51,732±1577</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/o atRA</td><td align="left" valign="bottom">52,586±2230</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/ 1 nM atRA</td><td align="left" valign="bottom">39,609±3180</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RARα.c156 w/ 100 nM atRA</td><td align="left" valign="bottom">33,593±4673</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D6 w/o atRA</td><td align="left" valign="bottom">47,130±3291</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D6 w/ 1 nM atRA</td><td align="left" valign="bottom">45,849±660</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">I RXRα.D6 w/ 100 nM atRA</td><td align="left" valign="bottom">43,021±1946</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref></td></tr><tr><td align="left" valign="bottom">OE RARα-Halo</td><td align="left" valign="bottom">233,732±3738</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref><break/><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref></td></tr><tr><td align="left" valign="bottom">OE Halo-RXRα</td><td align="left" valign="bottom">905,005±1464</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2B</xref><break/><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ SNAP</td><td align="left" valign="bottom">65,617±1293</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ RARα<sup>RR</sup>-SNAP</td><td align="left" valign="bottom">52,532±835</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ SNAP-RXRα</td><td align="left" valign="bottom">62,392±1532</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RARα w/ RARα-SNAP</td><td align="left" valign="bottom">37,255±371</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ SNAP</td><td align="left" valign="bottom">50,898±1791</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ RARα<sup>RR</sup>-SNAP</td><td align="left" valign="bottom">45,148±106</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ SNAP-RXRα</td><td align="left" valign="bottom">42,248±528</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr><tr><td align="left" valign="bottom">I RXRα w/ RARα-SNAP</td><td align="left" valign="bottom">58,880±1462</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2F</xref><break/><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Errors were calculated from three biological replicates.</p></fn></table-wrap-foot></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92979.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stasevich</surname><given-names>Timothy J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Colorado State University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study provides data that challenges the standard model that binding of Type 2 Nuclear Receptors to chromatin is limited by the available pool of their common heterodimerization partner Retinoid X Receptor. The evidence supporting the conclusions is <bold>compelling</bold>, utilizing state-of-the-art single-molecule microscopy. This work will be of broad interest to cell biologists who wish to determine limiting factors in gene regulatory networks.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92979.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This study provides compelling evidence that RAR, rather than its obligate dimerization partner RXR, is functionally limiting for chromatin binding. This manuscript provides a paradigm for how to dissect the complicated regulatory networks formed by dimerizing transcription factor families.</p><p>Dahal and colleagues use advanced SMT techniques to revisit the role of RXR in DNA-binding of the type-2 nuclear receptor (T2NR) RAR. The dominant consensus model for regulated DNA binding of T2NRs poses that they compete for a limited pool of RXR to form an obligate T2NR-RXR dimer. Using advanced SMT and proximity-assisted photoactivation technologies Dahal et al. now test the effect of manipulating the endogenous pool size of RAR and RXR on heterodimerization and DNA-binding in live U2OS cells. Surprisingly, it turns out that RAR, rather than RXR, is functionally limiting for heterodimerization and chromatin binding. By inference, the relative pool size of various T2NRs expressed in a given cell, rather than RXR, is likely determine chromatin binding and transcriptional output.</p><p>The conclusions of this study are well supported by the experimental results and provides unexpected novel insights in the functioning of the clinically important class of T2NR TFs. Moreover, the presented results show how the use of novel technologies can put long-standing theories on how transcription factors work upside down. This manuscript provides a paradigm for how to further dissect the complicated regulatory networks formed by T2NRs or other dimerizing TFs. I am convinced by the revised manuscript and have no additional concerns or comments.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92979.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In the manuscript &quot;Surprising Features of Nuclear Receptor Interaction Networks Revealed by Live Cell Single Molecule Imaging&quot;, Dahal et al combine fast single molecule tracking (SMT) with proximity-assisted photoactivation (PAPA) to study the interaction between RARa and RXRa. The prevalent model in the nuclear receptor field suggests that type II nuclear receptors compete for a limiting pool of their partner RXRa. Contrary to this, the authors find that over-expression of RARa but not RXRa increases the fraction of RXRa molecules bound to chromatin, which leads them to conclude that the limiting factor is the abundance of RARa and not RXRa. The authors also perform experiments with a known RARa agonist, all trans retinoic acid (atRA) which has little effect on the bound fraction. Using PAPA, they show that chromatin binding increases upon dimerization of RARa and RXRa.</p><p>The authors have done well to address my comments and specify limitations where they could not.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92979.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This study aims to investigate the stoichiometric effect between core factors and partners forming the heterodimeric transcription factor network in living cells at endogenous expression levels. Using state-of-the-art single-molecule analysis techniques, the authors tracked individual RARα and RXRα molecules labeled by HALO-tag knock-in. They discovered an asymmetric response to the overexpression of counter-partners. Specifically, the fact that an increase in RARα did not lead to an increase in RXRα chromatin binding is incompatible with the previous competitive core model. Furthermore, by using a technique that visualizes only molecules proximal to partners, they directly linked transcription factor heterodimerization to chromatin binding.</p><p>Strengths:</p><p>The carefully designed experiments, from knock-in cell constructions to single-molecule imaging analysis, strengthen the evidence of the stoichiometric perturbation response of endogenous proteins. The novel finding that RXR, previously thought to be a target of competition among partners, is in excess provides new insight into key factors in dimerization network regulation. By combining the cutting-edge single-molecule imaging analysis with the technique for detecting interactions developed by the authors' group, they have directly illustrated the relationship between the physical interactions of dimeric transcription factors and chromatin binding. This has enabled interaction analysis in live cells that was challenging in single-molecule imaging, proving it is a powerful tool for studying endogenous proteins.</p><p>Weaknesses:</p><p>None noted.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92979.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dahal</surname><given-names>Liza</given-names></name><role specific-use="author">Author</role><aff><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Thomas George Wade</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dailey</surname><given-names>Gina M</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Heckert</surname><given-names>Alec Basil</given-names></name><role specific-use="author">Author</role><aff><institution>University of California Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tjian</surname><given-names>Robert</given-names></name><role specific-use="author">Author</role><aff><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Darzacq</surname><given-names>Xavier</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>This study provides compelling evidence that RAR, rather than its obligate dimerization partner RXR, is functionally limiting for chromatin binding. This manuscript provides a paradigm for how to dissect the complicated regulatory networks formed by dimerizing transcription factor families.</p><p>Dahal and colleagues use advanced SMT techniques to revisit the role of RXR in DNA-binding of the type-2 nuclear receptor (T2NR) RAR. The dominant consensus model for regulated DNA binding of T2NRs posits that they compete for a limited pool of RXR to form an obligate T2NR-RXR dimer. Using advanced SMT and proximity-assisted photoactivation technologies, Dahal et al. now test the effect of manipulating the endogenous pool size of RAR and RXR on heterodimerization and DNA-binding in live U2OS cells. Surprisingly, it turns out that RAR, rather than RXR, is functionally limiting for heterodimerization and chromatin binding. By inference, the relative pool size of various T2NRs expressed in a given cell, rather than RXR, is likely to determine chromatin binding and transcriptional output.</p><p>The conclusions of this study are well supported by the experimental results and provide unexpected novel insights into the functioning of the clinically important class of T2NR TFs. Moreover, the presented results show how the use of novel technologies can put long-standing theories on how transcription factors work upside down. This manuscript provides a paradigm for how to further dissect the complicated regulatory networks formed by T2NRs or other dimerizing TFs. I found this to be a complete story that does not require additional experimental work. However, I do have some suggestions for the authors to consider.</p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) Does the increased chromatin binding measured when the RAR levels are increased reflect a higher occupancy of a similar set of loci, or are additional loci bound? The authors could discuss this issue in the context of the published literature. Obviously, this could be addressed experimentally by ChIP-seq or a similar analysis, but this would extend beyond the main topic of this manuscript.</p></disp-quote><p>We attempted to explore this experimentally using ChIP-seq with multiple RAR- and RXR-specific antibodies. Unfortunately, our results were inconclusive, as the antibody enrichment relative to the IgG control was insufficient for reliable interpretation. Specifically, our ChIP-seq enrichment levels were only around 1.5fold, while the accepted standard for meaningful ChIP enrichment is typically at least 2-fold. Due to these technical limitations, we decided to defer these experiments for now.</p><p>However, we agree with the reviewer that understanding whether the increased chromatin binding of RAR reflects higher occupancy at the same set of loci or binding to additional loci is a key question. In similar experiments involving the transcription factor TFEB (Esbin et al., 2024, <italic>Genes Dev</italic>, doi: 10.1101/gad.351633.124) where an increase in the SMT bound fraction occurred, both scenarios—higher occupancy at known loci and binding to additional loci in ChIP-seq was observed. So, addressing this intriguing possibility in future studies focused on RAR and RXR would be interesting.</p><disp-quote content-type="editor-comment"><p>(2) The results presented suggest convincingly that endogenous RXR is normally in excess to its binding partners (in U2OS cells). This point could be strengthened further by reducing RXR levels, e.g., by knocking out 1 allele or the use of shRNAs (although the latter method might be too hard to control). Overexpression of another T2NR might also help determine the buffer capacity of RXR.</p></disp-quote><p>We appreciate the reviewers’ acknowledgment that our results convincingly demonstrate that endogenous RXR is typically in excess relative to its binding partners in U2OS cells. We agree that this conclusion could be further reinforced by experiments such as overexpression of another T2NR to test RXR's buffering capacity. We are actively pursuing follow-up experiments involving overexpression of additional T2NRs to address this question in more detail. These studies are ongoing, and we plan to explore the buffer capacity of RXR more extensively in a future manuscript.</p><disp-quote content-type="editor-comment"><p>(3) The ~10% difference in fbound of RAR and RXR (in Figs 1 and 2), while they should be 1:1 dimers, is explained by invoking the expression of RXR isoforms. Can the authors be more specific concerning the nature of these isoforms?</p></disp-quote><p>We have provided detailed information about different T2NRs expressed in U2OS cells according to the Expression Atlas and the Human Protein Atlas Database in Supplementary Table S1. Table S1 specifically shows that both isoforms of RXRα and RXRβ are expressed in U2OS cells. Additionally, the caption of Table S1 explicitly notes the presence of isoform RXRβ in U2OS cells. In the main text, we reference Table S1 when discussing the 10% difference in fbound between RARα and RXRα, and we have now suggested that the expression of RXRβ likely accounts for the observed discrepancy.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In the manuscript &quot;Surprising Features of Nuclear Receptor Interaction Networks Revealed by Live Cell Single Molecule Imaging&quot;, Dahal et al combine fast single molecule tracking (SMT) with proximity-assisted photoactivation (PAPA) to study the interaction between RARa and RXRa. The prevalent model in the nuclear receptor field suggests that type II nuclear receptors compete for a limiting pool of their partner RXRa. Contrary to this, the authors find that over-expression of RARa but not RXRa increases the fraction of RXRa molecules bound to chromatin, which leads them to conclude that the limiting factor is the abundance of RARa and not RXRa. The authors also perform experiments with a known RARa agonist, all trans retinoic acid (atRA) which has little effect on the bound fraction. Using PAPA, they show that chromatin binding increases upon dimerization of RARa and RXRa.</p><p>Strengths:</p><p>In my view, the biggest strength of this study is the use of endogenously tagged RARa and RXRa cell lines. As the authors point out, most previous studies used either in vitro assays or over-expression. I commend the authors on the generation of single-cell clones of knock-in RARa-Halo and Halo-RXRa. The authors then carefully measure the abundance of each protein using FACS, which is very helpful when comparing across conditions. The manuscript is generally well written and figures are easy to follow. The consistent color-scheme used throughout the manuscript is very helpful.</p><p>Weaknesses:</p><p>(1) Agonist treatment:</p><p>The authors test the effect of all trans retinoic acid (atRA) on the bound fraction of RARa and RXRa and find that &quot;These results are consistent with the classic model in which dimerization and chromatin binding of T2NRs are ligand independent.&quot; However, all the agonist treatments are done in media containing FBS. FBS is not chemically defined and has been found to have between 10 and 50 nM atRA (see references in PMID 32359651 for example). The addition of 1 nM or 100 nM atRA is unlikely to result in a strong effect since the medium already contains comparable or higher levels of agonist. To test their hypothesis of ligand-independent dimerization, the authors should deplete the media of atRA by growing the cells in a medium containing charcoal-stripped FBS for at least 24 hours before adding agonist.</p></disp-quote><p>We acknowledge the reviewer's concern regarding the presence of atRA in FBS and agree that it may introduce baseline levels of agonist. However, in our experiments, both the 1 nM and 100 nM atRA treatments resulted in observable changes in RAR expression levels (Figure S3C). Additionally, the luciferase assays demonstrated that 100 nM atRA significantly increased retinoic acid-responsive promoter activity (Figure S1C). Given these clear responses to atRA, we believe the observed lack of effect on the chromatin-bound fraction cannot be attributed to the presence of comparable or higher levels of atRA in the FBS, as the reviewer suggests. Moreover, since our results align with the established literature and do not impact the core findings of our study, we decided not to pursue the suggested experiments with charcoal-stripped FBS in this manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Photobleaching and its effect on bound fraction measurements:</p><p>The authors discard the first 500 to 1000 frames due to the high localization density in the initial frames. This will preferentially discard bound molecules that will bleach in the initial frames of the movie and lead to an over-estimation of the unbound fraction.</p><p>For experiments with over-expression of RAR-Halo and Halo-RXR, the authors state that the cells were pre-bleached and that these frames were used to calculate the mean intensity of the nuclei. When pre-bleaching, bound molecules will preferentially bleach before the diffusing population. This will again lead to an over-representation of the unbound fraction since this is the population that will remain relatively unaffected by the pre-bleaching. Indeed, the bound fraction for over-expressed RARa and RXRa is significantly lower than that for the corresponding knock in lines. To confirm whether this is a biological result, I suggest that the authors either reduce the amount of dye they use so that this pre-bleaching is not necessary or use the direct reactivation strategy they use for their PAPA experiments to eliminate the pre-bleaching step.</p><p>As for the measurement of the nuclear intensity, since the authors have access to multiple HaloTag dyes, they can saturate the HaloTagged proteins with a high concentration of JF646 or JFX650 to measure the mean intensity of the protein while still using the PA-JFX549 for SMT. Together, these will eliminate the need to prebleach or discard any frames.</p></disp-quote><p>The Janelia Fluor dyes used in our experiments are known for their high photostability (Grimm et al., 2021, <italic>JACS Au</italic>, doi: 10.1021/jacsau.1c00006). During the initial 80 ms imaging to calculate the mean nuclear intensity, the laser power was kept at very low intensity (~3%) for a brief duration (~10 seconds), in contrast to the high-intensity (~100%) used during the tracking experiments, which span around 3 minutes. This low-power illumination does not induce significant photobleaching but merely puts the dyes in a temporary dark state. Therefore, this pre-bleaching step closely resembles the direct reactivation strategy employed in our PAPA experiments.</p><p>To further address the reviewer's concern, we performed a frame cut-off analysis for our SMT movies of endogenous RARα-Halo and over-expressed RARα-Halo (Figure S9B). The analysis shows no significant change in the bound fraction of either endogenous or over-expressed RARα-Halo when discarding the initial 1000 frames. Based on these results, we conclude that the pre-bleaching does not lead to an overestimation of the unbound fraction, and that our experimental approach is robust.</p><disp-quote content-type="editor-comment"><p>(3) Heterogeneous expression of the SNAP fusion proteins:</p><p>The cell lines expressing SNAP tagged transgenes shown in Fig S6 have very heterogeneous expression of the SNAP proteins. While the bulk measurements done by Western blotting are useful, while doing single-cell experiments (especially with small numbers - ~20 - of cells), it is important to control for expression levels. Since these transgenic stable lines were not FACS sorted, it would be helpful for the reader to know the spread in the distribution of mean intensities of the SNAP proteins for the cells that the SMT data are presented for. This step is crucial while claiming the absence of an effect upon over-expression and can easily be done with a SNAPTag ligand such as SF650 using the procedure outlined for the over-expressed HaloTag proteins.</p></disp-quote><p>We agree with the reviewer that there is heterogeneity in SNAP protein expression across the transgenic lines. In response to the reviewer’s suggestion, we performed the proposed experiment to assess the distribution of mean intensities for two key experimental conditions: Halo-RXRα with overexpressed RARα-SNAP and HaloRXRα with overexpressed RARαRR-SNAP. These results again confirm that the increase in chromatin-bound fraction of Halo-RXRα is observed only in the presence of RARα capable of heterodimerizing with RXRα, supporting our main conclusion (Figure S9).</p><p>For these experiments, we followed the same labelling procedure described in the methods section for tracking endogenous Halo-tagged proteins alongside transgenic SNAP proteins. As shown in Figure S9, for ~ 70 cell nuclei, the distribution of mean intensities is similar for both conditions, with the bound fraction of Halo-RXRα significantly increasing in the presence of RARα-SNAP compared to RARαRR-SNAP. This analysis underscores that the observed effects are indeed due to the functional differences between the two RARα variants rather than variability in expression levels.</p><disp-quote content-type="editor-comment"><p>(4) Definition of bound molecules:</p><p>The authors state that molecules with a diffusion coefficient less than 0.15 um2/s are considered bound and those between 1-15 um2/s are considered unbound. Clarification is needed on how this threshold was determined. In previous publications using saSPT, the authors have used a cutoff of 0.1 um2/s (for example, PMID 36066004, 36322456). Do the results rely on a specific cutoff? A diffusion coefficient by itself is only a useful measure of normal diffusion. Bound molecules are unlikely to be undergoing Brownian motion, but the state array method implemented here does not seem to account for non-normal diffusive modes. How valid is this assumption here?</p></disp-quote><p>We acknowledge the inconsistency in the diffusion coefficient thresholds for defining the chromatin-bound fraction used across our group’s publications. The choice of threshold or cutoff (0.1 µm²/s vs 0.15 µm²/s) is largely arbitrary and does not significantly impact the results. To validate this, we tested the effect of different cutoffs on fbound (%) for endogenously expressed Halo-tagged RARα and RXRα (Figure S10). As shown in Figure S10, there was no substantial difference in fbound (%) calculated using a 0.1 µm²/s versus 0.15 µm²/s cutoff (e.g., RARα clone c156: 47±1% vs 49±1%; RXRα clone D6: 34±1% vs 35±1%).</p><p>Since we have consistently applied the 0.15 µm²/s cutoff throughout this manuscript across all experimental conditions, the comparative analysis of fbound (%) remains valid. While we agree that a Brownian diffusion model may not fully capture the motion of bound molecules, our state array model accounts for localization error, which likely incorporates some of the chromatin motion features. Moreover, the distinction between bound (&lt;0.15 µm²/s) and unbound (1-15 µm²/s) populations is sufficiently large that using a normal diffusion model is reasonable for our analysis.</p><disp-quote content-type="editor-comment"><p>(5) Movies:</p><p>Since this is an imaging manuscript, I request the authors to provide representative movies for all the presented conditions. This is an essential component for a reader to evaluate the data and for them to benchmark their own images if they are to try to reproduce these findings.</p></disp-quote><p>We have now included representative movies for all the SMT experimental conditions presented in the manuscript. Please see data availability section of the manuscript.</p><disp-quote content-type="editor-comment"><p>(6) Definition of an ROI:</p><p>The authors state that &quot;ROI of random size but with maximum possible area was selected to fit into the interior of the nuclei&quot; while imaging. However, the readout speed of the Andor iXon Ultra 897 depends on the size of the defined ROI. If the ROI was variable for every movie, how do the authors ensure the same sampling rate?</p></disp-quote><p>We used the frame transfer mode on the Andor iXon Ultra 897 camera for our acquisitions, which allows for fast frame rate measurements without altering the exposure time between frames. Additionally, we verified the metadata of all our movies to ensure a consistent frame interval of 7.4 ms across all conditions. This confirms that the sampling rate was maintained uniformly, despite the variability in ROI size.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>(1) 'Hoechst' is mis-spelled.</p></disp-quote><p>We have now corrected this typo in the manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Cos7 appears in several places throughout the text. I assume this is a typo. If so, please correct it. If not, please explain if some experiments were done in Cos7 cells and kindly provide a justification for that.</p></disp-quote><p>The use of Cos7 cells is intentional and not a typo. Cos7 cells have been previously utilized in studies investigating the interaction between T2NRs (Kliewer et al., 1992, <italic>Nature</italic>, doi: 10.1038/355446a0). In our study, due to technical issues with antibodies for coIP in U2OS cells, we initially used Cos7 cells for control experiments to verify that Halo-tagging of RARα and RXRα did not disrupt their interaction, by transiently expressing the constructs in Cos7 cells. Following these control experiments, we confirmed the direct interaction of endogenously expressed RAR and RXR in U2OS cells with their respective binding partners using the SMT-PAPA assay. Since these results confirmed that Halo-tagging did not interfere with RAR-RXR interactions, we chose not to repeat the coIP experiments in U2OS cells.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>This study aims to investigate the stoichiometric effect between core factors and partners forming the heterodimeric transcription factor network in living cells at endogenous expression levels. Using state-of-the-art single-molecule analysis techniques, the authors tracked individual RARα and RXRα molecules labeled by HALO-tag knock-in. They discovered an asymmetric response to the overexpression of counter-partners. Specifically, the fact that an increase in RARα did not lead to an increase in RXRα chromatin binding is incompatible with the previous competitive core model. Furthermore, by using a technique that visualizes only molecules proximal to partners, they directly linked transcription factor heterodimerization to chromatin binding.</p><p>Strengths:</p><p>The carefully designed experiments, from knock-in cell constructions to singlemolecule imaging analysis, strengthen the evidence of the stoichiometric perturbation response of endogenous proteins. The novel finding that RXR, previously thought to be a target of competition among partners, is in excess provides new insight into key factors in dimerization network regulation. By combining the cutting-edge single-molecule imaging analysis with the technique for detecting interactions developed by the authors' group, they have directly illustrated the relationship between the physical interactions of dimeric transcription factors and chromatin binding. This has enabled interaction analysis in live cells that was challenging in single-molecule imaging, proving it is a powerful tool for studying endogenous proteins.</p><p>Weaknesses:</p><p>As the authors have mentioned, they have not investigated the effects of other T2NRs or RXR isoforms. These invisible factors leave room for interpretation regarding the origin of chromatin binding of endogenous proteins (Recommendations 4). In the PAPA experiments, overexpressed factors are visualized, but changes in chromatin binding of endogenous proteins due to interactions with the overexpressed proteins have not been investigated. This might be tested by reversing the fluorescent ligands for the Sender and Receiver. Additionally, the PAPA experiments are likely to be strengthened by control experiments (Recommendations 5).</p></disp-quote><p>We agree that this would be an interesting experiment. However, there are three technical challenges that complicate its implementation: First, as demonstrated in our original PAPA paper, dark state formation is less efficient when dyes are conjugated to Halo compared to SNAPf, making the reverse configuration less optimal. Second, SNAPf-tagged proteins have slower labeling kinetics than Halotagged proteins, often resulting in under-labeling of SNAPf. Third, our SNAPf transgenes were integrated polyclonally. Since background PAPA scales with the concentration of the sender-labeled protein, variable concentrations of the senderlabeled SNAPf proteins would introduce significant variability, complicating the interpretation of the background PAPA signal. Due to these concerns, we believe that performing reciprocal measurements with reversed fluorescent ligands may not yield reliable results.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>(1) The term &quot;Surprising features&quot; in the title is ambiguous and may force readers to search for what it specifically refers to. Including a word that evokes specific features might be helpful.</p></disp-quote><p>Our findings contradict previous work, which suggested that chromatin binding of T2NRs is regulated by competition for a limited pool of RXR. In contrast, we found that RAR expression can limit RXR chromatin binding, but not the other way around, which challenges the existing model. This unexpected result is what we refer to as a &quot;surprising feature&quot; in our title, and we believe it accurately reflects the novel insights our study provides. We also think that this is clearly conveyed in our manuscript abstract, supporting the use of &quot;Surprising features&quot; in the title.</p><disp-quote content-type="editor-comment"><p>(2) p.3, line 11 - The threshold of 0.15 μm2s-1 seems to be a crucial value directly linked to the value of fbound. What is the rationale for choosing this specific value? If consistent conclusions can be obtained using threshold values that are similar but different, it would strengthen the robustness of the results.</p></disp-quote><p>Please refer to our response to Reviewer #2’s Public Review point 4. The threshold choice is arbitrary and doesn’t affect the overall conclusions. To test this, we compared fbound (%) values calculated using both 0.1 μm²s-1 and 0.15 μm²s-1 cutoffs. For example, with endogenously expressed Halo-tagged RARα (clone c156), we observed fbound values of 47±1% vs 49±1%, and for RXRα (clone D6), 34±1% vs 35±1%, respectively (Figure S10). Since we have consistently applied the 0.15 μm²s-1 cutoff across all experimental conditions in this manuscript, the comparisons of fbound (%) between different conditions are robust and valid.</p><disp-quote content-type="editor-comment"><p>(3) p.4, line 13 - &quot;the fbound of endogenous RARα-Halo (47{plus minus}1%) was largely unchanged upon expression of SNAP (47{plus minus}1%)&quot; part of the sentence is not surprising. It would make more sense if it were expressed as &quot;the fbound of endogenous RARα-Halo (47{plus minus}1%) was largely unchanged upon expression of RXRα-SNAP (49{plus minus}1%), consistent with the control SNAP (47{plus minus}1%).&quot;.</p></disp-quote><p>We understand how the original phrasing may be confusing to the readers and have restructured the sentence as suggested by the reviewer for clarity.</p><disp-quote content-type="editor-comment"><p>(4) p.6, line 26 - The discussion that &quot;most chromatin binding of endogenous RXRα in U2OS cells depends on heterodimerization partners other than RARα&quot; seems to contradict the top right figure in Figure 4. If that's the case, the binding partner for the bound red molecule might be yellow rather than blue. Given a decrease in the number of RARα molecules with an unchanged binding ratio, the total number of binding molecules has decreased. Could it be interpreted that the potential reduction in RXRα chromatin binding, accompanying the decrease in binding RARα, is compensated for by other partners?</p></disp-quote><p>We agree with the reviewer that both the yellow and blue molecules in Figure 4 represent T2NRs that can heterodimerize with RXR. For simplicity, we chose to omit the depiction of RXR dimerization with other T2NRs (represented in yellow) in Figure 4. We have now included a note in the figure caption to clarify this. We plan to follow up on the buffer capacity of RXR with other T2NRs in a separate manuscript and will discuss this aspect in more detail once we have data from those experiments.</p><disp-quote content-type="editor-comment"><p>(5) Fig. 3 - I expected that DR localizations always appear more frequently than PAPA localizations by the difference in the number of distal molecules. Why does the linear line for SNAP-RXRα in Fig. 3 B have a slope exceeding 1? Also, although the sublinearity is attributed to binding saturation, is there any possibility that this sublinearity originates from the PAPA system like the saturation of PAPA reactivation? Control samples like Halo-SNAPf-3xNLS might address these concerns.</p></disp-quote><p>The number of DR and PAPA localizations depends on the arbitrarily chosen intensity and duration of green and violet light pulses. For any given protein pair, different experimental settings can result in PAPA localizations being greater than, less than, or equal to the number of DR localizations. Therefore, the informative metric is not the absolute number of DR and PAPA localizations, but rather how the ratio of PAPA to DR localizations changes between different conditions—such as between interacting pairs and non-interacting controls.</p><p>Regarding the sublinearity, we agree that it is essential to consider whether the observed sublinearity might stem from saturation of the PAPA signal. We know of two ways in which this could occur:</p><p>First, PAPA can be saturated as the duration of the green light pulse increases and dark-state complexes are depleted. However, this cannot explain the nonlinearity that we observe, because the duration of the green light pulse is constant, and thus the probability that a given complex is reactivated by PAPA is also constant. Likewise, holding the violet pulse duration constant yields a constant probability that a given molecule is reactivated by DR. PAPA localizations are expected to scale linearly with the number of complexes, while DR localizations are expected to scale linearly with the total number of molecules. Sublinear scaling of PAPA localizations with DR localizations thus implies that the number of complexes scales sublinearly with the total concentration of the protein.</p><p>Second, saturation could occur if PAPA localizations are undercounted compared to DR localizations. While this is a valid concern, we consider it unlikely in this case because (1) our localization density is below the level at which our tracking algorithm typically undercounts localizations, and (2) we observe sublinearity for RXR → RAR PAPA even though the number of PAPA localizations is lower than the DR localizations; undercounting due to excessive localization density would be expected to introduce the opposite bias in this case.</p><disp-quote content-type="editor-comment"><p>(6) Fig. 4 - The differences between A, B, and C on the right side of the model are subtle, making it difficult to discern where to see. Emphasizing the difference in molecule numbers or grouping free molecules at the top might help clarify these distinctions.</p></disp-quote><p>We appreciate the reviewer’s feedback. In response, we have revised Figure 4 by grouping the free molecules on the top right side for panels A, B and C, as suggested.</p><disp-quote content-type="editor-comment"><p>(7) While the main results are obtained through single-molecule imaging, no singlemolecule fluorescence images or trajectory plots are provided. Even just for representative conditions, these could serve as a guide for readers trying to reproduce the experiments with different custom-build microscope setups. Also, considering data availability, depositing the source data might be necessary, at least for the diffusion spectra.</p></disp-quote><p>We have now included representative movies for all the presented SMT conditions as source data. Please see data availability section of the manuscript.</p><disp-quote content-type="editor-comment"><p>(8) Tick lines are not visible on many of the graph axes.</p></disp-quote><p>We have revised the figures to ensure that the tick lines are now clearly visible on all graph axes.</p><disp-quote content-type="editor-comment"><p>(9) Inconsistencies in the formatting are present in the methods, such as &quot;hrs&quot; vs. &quot;hours&quot;, spacing between numbers and units, and &quot;MgCl2&quot;. &quot;u&quot; should be &quot;μ&quot; and &quot;x&quot; should be &quot;×&quot;.</p></disp-quote><p>We have corrected the formatting errors.</p><disp-quote content-type="editor-comment"><p>(10) Table S4, rows 16 and 17 - Are &quot;RAR&quot;s typos for &quot;RXR&quot;s?</p></disp-quote><p>We have corrected this in the manuscript.</p><disp-quote content-type="editor-comment"><p>(11) p.10~12 - Are three &quot;Hoestch&quot;s typos for &quot;Hoechst&quot;s?</p></disp-quote><p>This is now corrected in the manuscript.</p><disp-quote content-type="editor-comment"><p>(12) p.11, line 17 - According to the referenced paper, the abbreviation should be &quot;HILO&quot; in all capital letters, not &quot;HiLO&quot;.</p></disp-quote><p>This is now corrected in the manuscript.</p><disp-quote content-type="editor-comment"><p>(13) &quot;%&quot; on p.3, line 18, and &quot;.&quot; on p.6, line 27 are missing.</p></disp-quote><p>This missing “%” and “.” are now added.</p></body></sub-article></article>